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What is end stage renal disease?
Th e kidneys are complex organs traditionally known for their role in excretion of 
waste and excess water from the body. Besides, they also perform a spectrum of other 
functions essential for health such as helping to maintain blood pressure and assuring 
bone integrity. As they carry out these functions the kidneys work cooperatively and 
interactively with other organs systems, particularly the cardiovascular system.
Kidney disease can ultimately lead to the loss of kidney function and it can develop 
rapidly—acute kidney injury (AKI) or have long term pathology—chronic kidney 
disease (CKD).
Diabetic nephropathy followed by hypertension are the most common causes of CKD.
When not treated, CKD can progress to end-stage renal disease (ESRD). ESRD is a 
terminal illness defi ned as having a glomerular fi ltration rate less than 15 mL/min. Th e 
development of CKD and its progression to ESRD remains a major source of reduced 
quality of life and signifi cant premature mortality. Over the last decades the number 
of ESRD patients steadily increased worldwide. In the Netherlands, on January 2017, 
there were 17.132 ESRD patients and each year there are about 2000 new reported cases 
of ESRD1.
ESRD is fatal without renal replacement therapy (RRT).
How kidney failure treated and what is renal replacement therapy?
Kidney failure may be treated with hemodialysis (HD), peritoneal dialysis (PD) or 
kidney transplantation. On January 2017, in the Netherlands 32% (5450) patients were 
on HD and 63% (10812) received kidney transplant1.
In hemodialysis treatment, extracorporeal removal of waste products and extraction of 
fl uids is carried out directly via the blood, whereas peritoneal dialysis is carried out via 
the peritoneal cavity.
Treatment with HD may be performed at a dialysis unit or at home. In-center HD 
treatments are usually performed three times a week. Home HD and PD is generally 
done daily at home. 
According to the 2017 United States Annual Renal Data Report2 in 82% of the countries, 
HD is still the most common way of renal replacement therapy.
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What is hemodialysis vascular access? 
To be able to start hemodialysis therapy, a proper access site to a blood vessel with a high 
blood flow is required.
When urgent or emergent HD is needed central venous catheter (CVC) represent the 
only means for vascular access option (Figure 1a). However, this direct form of vascular 
access is not preferred for chronic dialysis treatment due to high risk of infections and 
central venous stenosis3,4.
To create a vascular access point in the upper extremity is preferred approach. Anatomical 
superficial location of veins in the low arm makes percutaneous cannulation easier and 
more suitable for regular use.
However, the blood flow in the low arm veins is not high enough for efficient dialysis. 
To allow high blood flow so that large amount of blood can pass through the dialyzer, 
a surgical connection between high pressure arterial system with a low pressure venous 
system is needed. A direct connection between the native artery and vein is called an 
arteriovenous fistula (AVF) (Figure 1b), when a prosthetic interposition between an 
artery and a vein is used it is called an arteriovenous graft (AVG) (Figure 1c).
According to the National Kidney Foundation Kidney Disease Outcomes Quality 
Initiative (NKF KDOQI)5, the placement of AVFs is currently regarded as the best 
available option for permanent vascular access, especially because of the lower rate of 
mortality, infections, thrombotic complications and a higher patency when compared 
to AVGs or CVCs6-8. However, a downside of the AVF is that it needs to be planned at 
least one or two months before starting HD, a time required for the proper “maturation” 
of the AVF.
Figure 1. Types of hemodialysis vascular access.
adapted from Atlas of Dialysis Vascular Access, Tushar J. Vachharajani
a. Central venous catheter c. Arteriovenous graftb. Arteriovenous fistula
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What is arteriovenous fi stula maturation?
According to the NKF KDOQI guidelines an AVF is matured and functional when the 
fi stula has the fl ow of > 600 mL/min, the vein has a minimum diameter of 6 mm2 and 
does not exceed the depth of 6 mm, and the margins are clearly identifi able.
For an AVF to successfully mature several functional and structural adaptations to the 
infl ow artery and outfl ow vein are required. Th e connection of a low-pressure vein to the 
high-pressure arterial circulation results in an immediate increase of blood fl ow and wall 
shear stress (WSS) through both the infl ow artery and the outfl ow vein9-11.
On a biological level, changes in WSS and wall tension are sensed by vascular endothelial 
cells, that convert hemodynamic stimuli into biochemical signals such as production of 
nitric oxide (NO) and growth factors that can trigger relaxation of vascular smooth 
muscle cells (VSMCs) resulting in acute vasodilatation12-14.
Upregulation of matrix metalloproteinases (MMPs) results in matrix degradation and 
restructuring of the vascular scaff old leading to luminal expansion15 but also to thickening 
especially of the venous wall16,17. Finally, successful vascular remodeling restores WSS 
toward normal levels in a vessel with increased blood fl ow and helps maintain luminal 
diameter18-20, a key hallmark of successful AVF remodeling.
Current concept of AVF maturation postulates that both, degrees of intimal hyperplasia 
(IH), which thickens the venous wall, narrows the luminal area, and predisposes to 
intravascular thrombosis together with adaptive restructuring of the vascular wall 
(outward remodeling [OR]), leading to luminal expansion of the arteriovenous conduct 
will ultimately determine luminal dimensions, fi stula fl ow and patency21,22 (Figure 2).
What does it mean an arteriovenous fi stula maturation failure?
While AVFs remain the most common vascular access, complications related to 
vascular access are one of the most common causes of hospitalization and morbidity in 
hemodialysis patients with approximately of $1 billion spent annually on health care 
costs23.
Th e utility of AVFs is hampered by two distinct causes of failure: (1) initial failure 
to mature, and (2) dysfunction of mature AVFs due to stenotic lesions in the venous 
outfl ow tract.
Recent quantitative study of the outcomes of fi stula patency and maturation reports that 
the primary and secondary patency rates for fi stulas at one year is an average 64%, and 
79% respectively. For fi stulas that were reported as mature, mean time to maturation 
was 3.5 months, however only 26% of created fi stulas were reported as mature at 6 
months and 21% of fi stulas were abandoned without use24.
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Figure 2. Vascular remodelling after fistula creation.
Healthy vein has the potential for successful outward remodelling (top left), whereas adequate maturation 
may be partially hindered by CKD-induced pre-existing intimal hyperplasia (IH) (top right). The net 
resultant of IH and outward remodelling may determine ultimate luminal calibre. adapted from Rothuizen 
et al., Nephrol Dial Transplant. 2013 May;28(5):1085-92
The exact mechanisms that lead to AVF maturation failure remain unknown, but 
both impaired OR and formation of IH are regarded as primary contributors to this 
pathophysiology21.
As previously discussed, the creation of an AVF results in an increase in shear stress, 
which causes vascular dilation in an attempt to return shear stress levels back to normal. 
As we try to create AVF in patients with severe vascular disease, it is possible that this 
conventional dogma may not always hold true. As an example, vascular calcification seen 
in elderly patients with diabetes mellitus, prevents endothelium to secrete mediators 
that are required for flow-mediated vasodilation.
Geometrical configuration of AVF may cause creation of difference in shear stress levels 
across the venous segment. In particular, at the site of arteriovenous anastomosis there 
are regions of low shear stress prone to inflammation. Increase in inflammation activates 
deposition of extracellular matrix (ECM) proteins, production of cytokines and growth 
factors, activation of proliferation and migration of VSMCs—all together creating 
focal areas of intimal hyperplasia and vasoconstriction25-27. There is an ongoing debate 
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about the anatomical origin of cells that are responsible for venous stenotic lesions in 
arteriovenous fi stulas28-32. Th is issue will be further elaborated in chapter 5 of this thesis.
Th e fact that AVF being the most favored access, exhibits failure rates that are among 
the highest for any elective surgical procedure, underscores the enormity of the issue of 
hemodialysis access dysfunction.
Th e focus of this thesis will be primarily on the novel strategies to prevent arteriovenous 
fi stula maturation failure.
Are there other alternatives to vascular access besides an 
arteriovenous fi stula?
As mentioned before, patients with ESRD require surgery to create a vascular access site 
for hemodialysis. For this purpose, native veins are generally preferred due to superior 
patency rates when compared to prosthetic grafts, but often unavailable due to preexisting 
vascular pathology often seen in patients with CKD33,34. Th e failure of synthetic vascular 
grafts predominantly results from the development of intimal hyperplasia ultimately 
leading to graft occlusion, and a relatively high risk of infectious complications3,35,36.
In recent years, tissue engineering strategies have made substantial progress to improve 
vascular access. Tissue engineered blood vessels could off er a better alternative to synthetic 
AV-grafts, when it is not possible to create an AV-fi stula. Indeed, tissue engineered blood 
vessels (TEBVs) can be tailor-made, are devoid of pre-existing vascular diseases and have 
the potential to adapt to changing hemodynamic conditions.
Can we engineer vascular tissue?
Several strategies to develop tissue engineered grafts have been described37. Th e 
majority of these approaches include complex in vitro preparation steps, decellularized 
scaff olds, or the incorporation of synthetic materials to generate TEBV. Ideally, vascular 
replacement should comprise of completely autologous cellular tissue, to avoid host-
immune reaction and hold the ability to remodel in vivo.
In our research group we developed a novel method to generate TEBVs by utilizing the 
foreign body response directed towards subcutaneously implanted polymeric rod that 
culminates in the formation of a fi brocellular tissue capsule (TC). Upon extraction of 
the polymer rod several weeks after implantation, the remaining tissue capsule is grafted 
into the vasculature, whereupon it diff erentiates into a blood vessel38.
Th us far, the origin of cells in these TCs remained unknown. In chapter 6 of this thesis, 
this topic will be discussed further.
Beshaeva.indd   13 7-1-2019   12:58:45
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Scope of this thesis
Previously, we established a unique murine model of arteriovenous fistula, which has 
a configuration similar to the one most frequently used in humans (venous end-to-
arterial side)25. This thesis includes subsequent studies of this model designed to evaluate 
new therapeutic strategies aimed to improve patency of AV-fistulas and to unravel the 
pathophysiology of AVF failure.
In addition, we further expand our understanding on the cellular origin of tissue capsules 
for autologous tissue engineering, as an alternative to AV-grafts.
It is known that the process of vascular adaptation after AVF creation is associated with 
an excessive inflammatory response characterized by the infiltration of macrophages and 
lymphocytes as well as the up regulation of pro-inflammatory cytokines30,39.
In chapter 2 and 3 of this thesis we further examined the contribution of inflammation 
to AVF failure.
In chapter 2 we studied the complex role of toll-like receptor 4 (TLR4) homologue -RP105 
in AVF remodeling. Here we hypothesized that in mice deficient for RP105 pro-
inflammatory TLR4 signaling is upregulated, which results in worsening of AVF 
maturation.
We created AVFs in RP105 deficient mice to study the effect on AVF maturation in 
vivo. In addition, in series of in vitro studies we defined cell-specific effects of RP105 on 
macrophages and VSMCs. 
In another study, described in chapter 3, we evaluated the feasibility and efficacy of 
prednisolone—a potent anti-inflammatory drug. To improve local biological activity 
and reduce systemic side-effects prednisolone was encapsulated in liposomes, a potent 
vehicle for targeted drug delivery to inflamed organs.
In chapter 4 we assessed the role of the relaxin (RLN2) pathway in AVF remodeling. 
Relaxin is a hormone exhibiting its action on the vasculature via interaction with 
its receptor (RXFP1), resulting in vasodilatation, ECM remodeling and decreased 
inflammation—favorable effects for successful AVF maturation. In view of the emerging 
role of the RLN2-RXFP1 axis in vascular remodeling and inflammation, we examined 
the consequences of disturbing this hormone-receptor balance in AVF maturation. For 
this purpose, we used murine AVF model in which we studied the effect of RXFP1 
deficiency on fistula remodeling. Furthermore, we determined the effects of RXFP1 
deficiency on the phenotype and function of VSMCs in vitro.
The pathophysiology of arteriovenous fistula maturation failure is associated with 
impaired outward remodeling and intimal hyperplasia21.  In chapter 5, based on the 
work of Liang and co-workers29 the on-going debate about the cellular origin of cells 
forming intimal hyperplasia and venous stenosis in AVFs is discussed.
Beshaeva.indd   14 7-1-2019   12:58:47
General introduction |   15
In parallel with testing new therapeutics to improve maturation and patency of native 
AVFs, our group is working on developing TEBVs, which could off er a suitable 
alternative for arteriovenous conduits, circumventing the limitations of synthetic grafts 
and avoiding the need for maturation of fi stulas.
In chapter 6, a lineage tracing study is described to elucidate the contribution of bone 
marrow derived cells to TEBV formation. We established a rat model where cells of 
the hematopoietic lineage are labeled with green fl uorescent protein. For the clinical 
application of the in situ engineered vascular grafts, we focus on patients with ESRD 
that require a vascular access for hemodialysis. Th erefore, we combined bone marrow 
lineage tracing with a model of CKD to investigate the eff ect of chronic kidney failure 
on tissue capsule composition.
Finally, chapter 7 gives an overall summary of the research presented in this thesis and 
discusses future prospective on vascular access for hemodialysis to reduce morbidity in 
ESRD patients.
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Chapter 2
Defi ciency of TLR4 homologue 
RP105 aggravates outward 
remodeling in a murine model of 
arteriovenous fi stula failure.
Taisiya Bezhaeva, ChunYu Wong, Margreet R. de Vries, 
Eric P. van  der Veer, Carla M.A. van Alem, Ivo Que,  
Reshma A. Lalai, Anton Jan van Zonneveld, 
Joris I. Rotmans and Paul H.A. Quax
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Abstract
Arteriovenous access dysfunction is a major cause of morbidity for hemodialysis 
patients. The pathophysiology of arteriovenous fistula (AVF) maturation failure 
is associated with inflammation, impaired outward remodeling (OR) and intimal 
hyperplasia. RP105 is a critical physiologic regulator of TLR4 signaling in 
numerous cell types. In the present study, we investigated the impact of RP105 
on AVF maturation, and defined cell-specific effects of RP105 on macrophages 
and vascular smooth muscle cells (VSMCs). Overall, RP105-/- mice displayed 
a 26% decrease in venous OR. The inflammatory response in RP105-/- mice 
was characterized by accumulation of anti-inflammatory macrophages, a 76% 
decrease in pro-inflammatory macrophages, a 70% reduction in T-cells and a 
50% decrease in MMP-activity. In vitro, anti-inflammatory macrophages from 
RP105-/- mice displayed increased IL10 production, while MCP1 and IL6 
levels secreted by pro-inflammatory macrophages were elevated. VSMC content 
in RP105-/- AVFs was markedly decreased. In vitro, RP105-/- venous VSMCs 
proliferation was 50% lower, whereas arterial VSMCs displayed a 50% decrease 
in migration, relative to WT. 
In conclusion, the impaired venous OR in RP105-/- mice could result from 
a shift in both macrophages and VSMCs towards a regenerative phenotype, 
identifying a novel relationship between inflammation and VSMC function in 
AVF maturation.
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Introduction
Th e placement of an arteriovenous fi stula (AVF) is currently regarded as the 
best available option for permanent vascular access in patients requiring chronic 
hemodialysis. For proper maturation of the AVFs, both a major increase in 
blood fl ow and venous diameter are required to allow adequate hemodialysis 
treatment. However, several clinical trials have shown that the 1-year primary 
patency rate of AVFs does not exceed 60%, illustrating the fact that the need for 
further improvement of this access conduit is vital1,2. AVF-related complications 
are frequently encountered shortly after AVF surgery, as 30-60% of the AVF fail 
to mature adequately to support dialysis therapy3. Th e exact mechanisms that 
lead to AVF maturation failure remain unknown, but both impaired outward 
remodeling (OR) and formation of intimal hyperplasia (IH) are regarded as primary 
contributors to this pathophysiology4. Recent studies have shown that the process of 
vascular adaptation after AVF creation is associated with an excessive infl ammatory 
response5-8 and proliferation and migration of arterial and venous vascular smooth 
muscle cells (VSMCs) towards the intima at the site of anastomosis9-11. In view 
of extensive adverse consequences resulting from AVF failure and the subsequent 
burden for hemodialysis patients, there is increasing emphasis on pathophysiological 
studies aimed to unravel the complex mechanisms underlying AVF failure. Th e 
latter is pivotal in eff orts to identify novel molecular therapeutic targets that could 
potentially improve AVF patency.
Toll-like receptor 4 (TLR4) is a well-known sentry that induces a pro-infl ammatory 
signaling cascade12. Its function is modulated not only by exogenous pathogens 
in the context of microbial infections13, but also by several endogenous stimuli 
in infl ammatory conditions such as atherosclerosis14,15 or during vascular 
remodeling16-19. To initiate the TLR4 signaling cascade, activation of its adaptor 
molecule MD2 is required which is responsible for the recognition of bacterial 
lipopolysaccharide (LPS) on the cell surface20. Due to the hierarchical importance 
of  TLR4 in the innate immune response and its ubiquitous function, the signaling 
activity of this protein is fi rmly regulated by several regulatory molecules. One such 
regulator is RP105 (radioprotective 105, also known as CD180), a cell surface protein 
expressed  by  numerous  cell  types,  including  infl ammatory  cells  and  VSMCs21,22. 
Th e structure of RP105 is evolutionarily similar to TLR4 and it associates with 
MD1, a MD2 homologue which promotes RP105 cell surface expression23,24. 
RP105–MD1 exerts dichotomous regulatory activities on TLR4-mediated LPS 
responses in a cell type-dependent fashion25. On B-cells, RP105-MD1 drives 
cellular proliferation and enhances B-cell-dependent infl ammatory processes26. In 
contrast, in myeloid cells, RP105 acts as a   natural antagonist  of  TLR4  signaling27, 
while  the  functional  role  in  VSMCs  remains   poorly understood. Previous 
studies from our group have demonstrated that RP105 defi ciency results in decreased 
atherosclerotic lesion formation via alterations on pro-infl ammatory B-cells28 and 
a CCR2-dependent decrease in monocyte infl ux29. Strikingly, complete opposite 
eff ects were observed in a murine model of vein graft disease, where a 90% increase 
in graft lesion area was linked to a local increase in macrophage content and lesional 
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levels of monocyte chemoattractant protein-1 (MCP1), expressed by VSMCs21. In a 
model of post-interventional vascular remodeling, artery cuff placement in RP105-/- 
mice resulted in increased neointima formation, which coincided with an increase in 
arterial VSMC proliferation ex vivo22.
In the context of both AVF maturation and failure, numerous cell types are involved 
including inflammatory cells and VSMCs from both the feeding artery10,30 and local 
venous wall31, making it a unique model to unravel specific functional consequences of 
RP105 on remodeling in AVF.
In the present study, we aimed to elucidate the role of RP105 on AVF maturation in a 
murine model of AVF failure by assessing cell type-specific effects of RP105 deficiency, 
on macrophage polarization and VSMC behavior.
Results
RP105 deficiency influence AVF maturation
To investigate how differential expression of RP105 could influence AVF maturation, 
we created an AVF by an end-to-side ligation of the jugular vein to the carotid artery 
of wild-type (WT) and RP105-/-. Two weeks after surgery the tissue was processed to 
paraffin, and 5-µm sections were made perpendicular to the vein at 12 locations 
with an interval of 150 µm. Because most of the stenotic lesions in human AVFs 
occur in the venous outflow tract we analyzed first 3 consecutive venous sections 
downstream from the area closest to the anastomosis. AVF material was evaluated 
using morphometric and immunohistochemical approaches. RP105-/-mice 
showed a 26% smaller circumference of the external jugular vein compared to 
WT mice (P=0.03) (Figure 1a), indicating that RP105 deficiency impacts outward 
remodeling. As shown in Figure 1b, diminished RP105 expression did not influence 
IH in the venous outflow tract of the AVF. Importantly, immunohistochemical 
staining revealed that the vast majority of intimal cells are αSMA+ in both WT and 
RP105-/- mice (Figure 1b).
Beshaeva.indd   24 7-1-2019   13:00:12
Targeting infl ammation: Th e role of RP105 in arteriovenous fi stula failure |   25
Figure 1. Eff ect of RP105 defi ciency on AVF maturation in vivo. 
(a) Quantifi cation of morphometric parameters. Decrease in vessel circumference (outward remodeling) in 
RP105 defi cient mice was observed 14 days after AVF creation, as compared to WT. Lumen and intimal 
hyperplasia did not diff er between RP105-/- and WT mice. (b) Histological staining of venous outfl ow 
tract 14 days after surgery. Weigert elastin staining was used to determine histomorphometrical parameters 
of the vessel. Circumference (internal elastic lamina area) was used to quantify outward remodeling (red 
line). Intimal hyperplasia (green arrow) measured as a diff erence between luminal area (blue line) and vessel 
circumference. αSMA staining shows area of intimal hyperplasia 14 days after AVF creation. (#) intimal 
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RP105 deficiency leads to reduced VSMC proliferation in AVF lesions
Given this VSMC enrichment in the intimal region of mature AVF, we sought to 
determine the proliferation capacity of these cells immunohistochemically. For this, 
we quantitated the amount of proliferating αSMA+/Ki67+ cells in AVF sections. These 
studies revealed a 31% decrease in αSMA+/Ki67+ VSMCs in RP105-/- mice, as compared 
to WT mice (Figure 2a).
Since both arterial and venous VSMC might contribute to the portion of proliferating 
VSMC and we cannot discriminate between arterial and venous VSMCs in vivo, this 
borderline significance in the number of αSMA+/Ki67+ VSMCs (P=0.07) might be 
relevant (Figure 2b).
Figure 2. Effect of RP105 deficiency on VSMC proliferation in vivo. 
Immunofluorescent staining (a) and quantification (b) of αSMA+/Ki67+ cells (white arrows) revealed 
reduction in number of proliferating VSMCs in AVF lesions of RP105-/- mice compared to WT 14 days 
after AVF surgery. n=11 per group. Bar=100 µm. 
Diminution of RP105 differently affects arterial and venous VSMC function
To further dissect the contribution of arterial and venous VSMCs to AVF maturation 
and failure, we elected to study the consequences of differential RP105 expression in 
arterial and venous VSMCs ex vivo. For this, we cultured explant material from the 
carotid artery and vena cava of WT and RP105-/- mice for 2 weeks. Morphologically, 
we observed that arterial VSMCs  possessed  an  elongated  phenotype,  whereas 
venous  cells  had  a  more stellate appearance (Figure 3a). Both arterial and venous 
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gene expression of VSMCs markers (smooth muscle α-actin (SMA), myosin heavy 
chain (MYHC) and calponin) after 2 weeks of culture (Figure 3b). Th e phenotypic 
diff erence and the vascular origin of arterial versus venous VSMCs was confi rmed 
by assessing EphB4 expression levels, an established embryological marker of venous 
origin32,33, which was increased in cultured venous VSMCs up to 2 weeks after 
isolation (Figure 3c). 
Figure 3. In vitro cultured arterial and venous VSMCs. 
(a) Microscopic representation of morphological diff erence between cultured arterial and venous SMCs. 
Bar=100µm, x200 magnifi cation. (b) VSMCs phenotype after 14 days in culture was confi rmed by stable 
mRNA expression levels of smooth muscle α-actin (SMA), myosin heavy chain (MHC) and calponin. (c)
Stable increase in EphB4 mRNA levels was detected in venous SMCs isolated from WT and RP105-/- mice. 
Cells were maintained in culture for 14 days. *P<0.05; n=3.
Next, we further determine expression levels of RP105 associating molecules. 
Interestingly, RT-PCR analysis of RP105 by WT VSMCs revealed a striking > 100-fold 
increase in gene expression on venous VSMCs as compared to arterial VSMCs (Figure 
4a). Expression of its accessory molecule MD1 was also elevated > 100-fold on venous 
VSMCs isolated from both WT and RP105-/- mice (Figure 4b). mRNA levels of 
infl ammatory marker TLR4 was elevated by 48% in venous cells, as compared to arterial 
VSMCs (Figure 4c). Expression of the TLR4 accessory molecule MD2 did not diff er 
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Figure 4. Difference in mRNA expression levels between arterial and venous VSMCs in vitro.
(a) RP105, (b) MD1, (c) TLR4. The relative expression normalized to GAPDH. *P<0.05; n=3.
Functionally, venous VSMCs derived from RP105-/- mice displayed a 50% reduction in 
their rate of proliferation, relative to VSMCs derived from WT mice, while arterial 
VSMCs proliferation was unaltered (Figure 5a). In contrast, migratory capacity was 
reduced by 50% over a 16h time period in arterial VSMCs derived from RP105-/-, venous 
SMCs showed no difference in migration between WT and RP105-/- mice (Figure 5a). As 
VSMCs are also potent cytokine producers we measured amount of pro-inflammatory 
cytokines IL6 and MCP1 secreted by arterial and venous VSMCs from WT and 
RP105-/- mice. Although there was no difference in IL6 and MCP1 levels between WT 
and RP105-/-, venous VSMCs isolated from both WT and RP105-/- mice exhibited higher 
inflammatory state characterized by 70% and 84% increase in IL6 secretion by WT and 
RP105-/- VSMCs respectively when compared to arterial VSMC and 57% and 61% 
upregulation in MCP1 levels produced by WT and RP105-/- VSMCs respectively when 
compared to arterial VSMCs (Figure 5b). There was no difference in the amount of anti-
inflammatory cytokine IL10 produced either by arterial or venous VSCMs from WT 
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Figure 5. Functional diff erence between arterial and venous VSMCs in vitro. 
(a) Reduction in proliferative rate was limited to VSMCs isolated from RP105-/-  veins. Decrease in 
migration of VSMCs isolated from RP105-/- mice was restricted  to arterial cells only. Proliferation rate and 
migration were measured over 16h time period. (b) Venous VSMCs isolated from WT and RP105-/- mice 
produce signifi cantly higher amounts of infl ammatory cytokines IL6 and MCP1. Cells were maintain in 
culture for 14 days. (*) P<0.05; n=3.
RP105 defi ciency impacts the infl ammatory status of AVF infi ltrating cells
To gain insight into the consequences of diff erential expression of RP105 on the 
infl ammatory response to injury in vivo, we evaluated the infl ammatory cell composition 
of AVFs in RP105-/- and WT mice. Analysis of AVF material 2 weeks after surgery 
revealed a 76% reduction in MAC3+/CCR2+ pro-infl ammatory macrophages cell 
number in the venous lesions of RP105-/- mice. Furthermore, the number of 
infiltrating MAC3+/CD206+ anti-inflammatory macrophages was increased by 35%, 
as compared to WT mice (Figure 6a). Th e number of CD3+ T-lymphocytes in RP105-/- 
mice was decreased by 70% (Figure 6b). Interestingly, we observed an enrichment 
of these infl ammatory cells in the adventitial layer of the vessel (Figure 6a, b). No 
changes between RP105-/- and WT mice were found in the number of MCP1+ cells in 
the AVF lesions at 2 weeks after surgery (Supplementary Figure 3). Notably, the 
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creation was skewed towards a tissue repair, or regenerative state. More than 90% of all 
MAC3+ cells were CD206+, a cell surface protein that defines the anti-inflammatory 
repair associated macrophage phenotype, whereas but 6% of these MAC3+ macrophages 
were found to express CCR2, the pro-inflammatory macrophage marker.
Figure 6. Effects of RP105 deficiency on inflammatory response in vivo. 
Quantification and immunohistochemical staining of (a) MAC3+/CCR2+ macrophages and MAC3+/CD206+ 
macrophages (white arrows) and (b) CD3+ T-lymphocytes (black arrows) in AVF lesions 14 days after surgery. 
Decrease in cell number of pro-inflammatory macrophages and upregulation of anti-inflammatory macrophages 
upon RP105 deletion was observed. Bar=100 µm. Number of CD3+ T-lymphocytes was reduced in 
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Macrophage-mediated cytokine production is aff ected by RP105 expression 
levels 
Having identifi ed that AVFs in RP105-/- mice are enriched for anti-infl ammatory 
macrophages, we subsequently isolated bone marrow from WT and RP105-/- mice and 
polarized bone marrow-derived macrophages towards either pro- or anti-infl ammatory 
phenotypes with LPS/IFN-gamma or IL4/IL13 treatment for 24h, respectively. We 
observed an augmented infl ammatory response by pro-infl ammatory macrophages 
derived from RP105-/- mice as evidenced by a 40% increase in MCP1 secretion and a 
73% up regulation in IL6  production,  as  compared  to  macrophages  obtained  from 
WT  mice  (Figure 7a).
Macrophages that were isolated from RP105-/- mice and driven towards the anti-
infl ammatory phenotype exhibited a 72% increase in anti-infl ammatory cytokine IL10 
production as compared to WT macrophages (Figure 7b).
Figure 7. Eff ect of RP105 defi ciency on macrophage function. 
(a) Bone marrow-derived macrophages from RP105-/- primed towards pro-infl ammatory phenotype secrete 
increased levels of MCP1 and IL6 as compared to WT control mice. (b) Anti-infl ammatory macrophages 
from RP105-/- secrete increased levels of repair assicoated cytokine IL10. *P<0.05; n=3.
MMP activity is decreased in AVF lesions of RP105 defi cient mice
Matrix metalloproteinases (MMPs) are known for the role they play in extracellular 
matrix (ECM) remodeling, such as collagen and elastin. MMP-mediated degradation 
of the ECM is critically involved in vascular remodeling following AVF placement 
and during AVF maturation34. We assessed MMP activity in the lesions using in vivo 
near-infrared fl uorescent imaging. We observed a two-fold reduction (6.3±1.6 WT vs. 
2.9±0.2 RP105-/- AU) in fl uorescence intensity indicating reduced in vivo MMP activity 
in RP105-/- mice as compared to WT (Figure 8). 
Pro-inflammatory macrophages
priming with IFNγ and LPS
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Figure 8. In vivo near-infrared biofl uorescent imaging and quantitative analysis of MMP 
activity. 
(a) Visual representation of near-infrared signal from active MMPs. Accumulation of green color can be 
seen in the anastomotic region 24h after injection of MMPSenseTM 680 probe. *P<0.05; n=4 per group. 
(b)  Quantitative analysis of fl uorescent intensity showed decrease in MMP activity in RP105-/- mice, as 
compared to WT. 
RP105 is present in the venous wall of human AVF
Human AVF was obtained in the operating room during AVF correction surgery and 
processed in the same manner as mouse samples. Immunohistochemical staining of 
human AVF sections showed an impressive accumulation of RP105 expression within 
the venous wall. Cells positive for RP105 were mainly located in the neointima (Figure 
9).
Figure 9. RP105 expression in human AVF. 
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Discussion
In this study, we addressed the specifi c role of TLR4 homologue RP105 in vascular 
remodeling, infl ammation and VSMCs function in a murine model of AVF failure. Th e 
process of AVF maturation is complex and integrates several cellular responses, including 
the infi ltration of infl ammatory cells shortly after AVF surgery5,35. In addition, VSMCs 
play a pivotal role in AVF maturation as they contribute to thickening of the venous 
vessel wall and the concurrent outward remodeling. Here, we clearly show that RP105 
defi ciency aff ects the infl ammatory and VSMC-mediated response to injury during the 
course of AVF maturation, accumulating in an impaired outward remodeling 14 days 
after the placement of an AVF. 
A vital aspect of AVF maturation involves the outward remodeling response, a vessel 
widening process that is tightly coupled with VSMC proliferation. While VSMC 
proliferation in  IH  is  generally  considered  to  be  detrimental,  the  process 
is  benefi cial  for vascular adaptation in AVF, especially in the early phase of AVF 
maturation. To this end, the reduction in venous outward remodeling in RP105-/- 
mice, coupled with a reduction in proliferating venous VSMC within AVFs and 
ex vivo, suggests that inhibiting VSMCs proliferation (and migration) could be 
detrimental for long-term AVF maturation.
A striking observation in our studies was that RP105 diminution diff erentially 
aff ected arterial and venous VSMCs, as evidenced by RP105-specifi c eff ects on 
proliferation and infl ammatory cytokine production by venous cells as well as impact 
on arterial migration. Th e endogenous expression levels of RP105 in arterial and 
venous VSMCs support this fi nding, along with diff erential expression profi les of 
associating TLR4-family members (including TLR4 and MD1). Collectively, these 
fi ndings suggest that the susceptibility for infl ammatory stimuli could potentially 
diff er between arterial and venous VSMCs. Importantly, our studies support the 
notion that numerous cell sources are involved in venous IH in AVF (including 
resident venous cells, infi ltrating arterial cells, and circulating bone marrow-derived 
cells7,36-39). Furthermore, our studies illustrate the need for continued investigation 
of the phenotypic properties and functional characteristics of VSMCs in AVFs, in 
particular due to the contrasting lineage tracing studies detailing a predominance of 
arterial VSMCs10 versus venous VSMCs31 in venous IH following AVF placement.
Increased expression of the pro-infl ammatory mediators IL6, TNF and MCP1 are 
associated with AVF failure8,40,41, while the reduction of anti-infl ammatory molecule 
heme oxygenase-1 (HO-1) is linked to AVF failure42-44. In our study, we demonstrated 
that the polarization of macrophages isolated from the bone marrow of RP105-/- mice 
towards the pro- or anti-infl ammatory phenotypes appears to remove a regulatory 
repressor, as both phenotypes displayed an up regulation of signature cytokines being 
produced. Th e augmentation of pro-infl ammatory cytokine production in RP105-/- 
macrophages is in keeping with RP105 being an antagonist of pro-infl ammatory TLR4 
signaling25,27,45, while the spike in IL10 production is supported by recent reports that 
low grade infl ammation triggers bone marrow-derived macrophages to generate anti-
infl ammatory cytokines in a TLR4 dependent fashion46. 
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AVF placement in RP105-/- mice yielded decreased MAC3+/CCR2+ macrophages 
and CD3+ T-lymphocytes. Our previous study performed by Wezel et al. on the 
role of RP105 in atherosclerosis showed the same difference which was linked to 
decrease in CCR2+ monocytes in RP105-/- mice hampering process of monocyte 
infiltration into the lesions. After additional in vitro stimulation with LPS the 
dose dependent decrease in CCR2 expression on CCR2+ monocytes isolated from 
RP105-/- mice was observed which may point onto increased signaling via TLR4 
route29. A noteworthy observation two weeks after AVF placement in RP105-/- mice 
was the attenuation of vessel wall MMP activity. While the type of vascular injury 
impacts the degree by which MMPs remodel the vascular wall, these factors also 
play a role in determining which MMPs are activated47, and could differ between 
arterial and venous segments. Castier et al. reported that increased MMP-9 activity 
coincided with increased OR in the arterial segment of the AVF48, while Nieves 
Torres et al. demonstrated that MMP inhibition enhanced venous OR in AVF49. 
Our studies contradict this finding, and suggest instead that decreased MMP limits 
venous OR in maturating AVFs.
During the process of vascular remodeling the initial pro-inflammatory reaction is 
gradually changing towards resolution of inflammation characterized by accumulation 
of anti-inflammatory cells50-53. The specific dynamics with regard to pro-/anti- 
inflammatory response in the context of AVF maturation is still unknown. In our 
murine model, RP105 deficiency caused significant increase in MAC3+/CD206+ 
anti-inflammatory macrophages in the venous lesions of AVF, compared to controls. 
Overall prevalence in anti-inflammatory population (93.7%), compared to 6.3% of 
pro-inflammatory macrophages at 2 weeks after AVF creation might suggest either 
that in the current model pro-inflammatory response is completed at earlier time 
points or that anti-inflammatory macrophages play a dominant role in the tissue 
response in murine AVF. Thus, despite the increased production of both pro- and 
anti-inflammatory cytokines by macrophages in vitro, the effect of RP105 deletion 
on anti-inflammatory macrophages was dominant in the venous lesions of murine 
AVF.
Finally, to our knowledge it is the first study to demonstrate expression of RP105 in 
human AVF, which is an important observation supporting further research related 
to RP105 as a potential therapeutic target to improve AVF maturation.
Study limitations
Current study is performed in mice, which do not precisely mimic the human 
inflammatory response to injury; however this model remains highly useful for 
studying the vital pathophysiological aspects of AVF maturation and failure. Another 
limitation is the absence of uremia, given that a recent in vivo study by Kang et 
al. demonstrated that fistula maturation in mice is affected by CKD44. Here, the 
chronic accumulation of waste products and uremic toxins in the blood impacted 
AVF flow, resulting in increased venous wall thickness and thrombus formation. 
Also, future studies should include flow measurements, as the rate of blood flow is 
critical functional parameter of AVF.
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In conclusion, our study demonstrates the complex role of RP105 in VSMCs and 
macrophages in a murine model of AVF. Th e design and implementation of therapeutic 
strategies targeting the TLR4/RP105 axis to prevent AVF failure must include cell 
specifi c targeting approaches and be temporally controlled.
Material and Methods
Animals
Murine model of AVF failure
Th is study was performed in compliance with Dutch government guidelines and the 
Directive 2010/63/EU of the European Parliament. All animal experiments were 
approved by the Institutional Committee for Animal Welfare of Leiden University 
Medical Center. RP105-/- mice (C57BL/6 background) were obtained from the local 
animal breeding facility, WT C57BL/6 mice were obtained from Charles River. Adult 
male mice aged 10-11 weeks were used for the experiments. AVFs were created in an 
end-to-side manner between the dorsomedial branch of the external jugular vein and 
the common carotid artery as previously described5,54 (Supplementary Methods S1). Th e 
mice were euthanized at 2 weeks after AVF surgery.
In vivo near-infrared MMPs assay
In vivo MMP activity of endogenous MMP-2, -3, -9, -12 and -13 was assessed by 
injecting fl uorescent imaging agent MMPSenseTM 680 from PerkinElmer’s (Waltham, 
MA, USA) which is activated in the presence of active MMPs55. First, AVF was created as 
described above (n=4 per group). 14 days later mice were anesthetized under isofl urane 
and 4 nmol of MMPSenseTM 680 probe were injected into the tail vein. 24 hours later, 
mice were placed under anesthesia, AVF was dissected and mice were scanned using the 
Optix MX2 optical imaging system. Excitation was performed with a 670-nm pulsing 
laser, and emission was detected with a 693-nm long-pass fi lter. Lifetime analysis was 
used to confi rm the specifi city of MMP-activated probes. Fluorescence intensities and 
fl uorescence lifetime were expressed in pseudo colors and projected on the bright fi eld 
grayscale image of the mouse. Quantifi cation of the fl uorescent intensity was performed 
using the Optiview 2.2 software as described previously56.
Tissue harvesting and processing
14 days after surgery, the mice were anesthetized using isofl urane whereupon the AVF 
was dissected. After a thoracotomy, the inferior vena cava was transsected followed by 
a mild pressure perfusion fi xation with 4% formalin through an intracardiac perfusion. 
Th e tissue was embedded in paraffi  n and 5 µm-thick sections of the venous outfl ow tract 
were made perpendicular to the vein with an interval of 150 µm.
Morphometric and histological analysis
Morphometric analysis was performed on Weigert’s elastin stained sections using ImageJ 
software. Vessel circumference as a parameter displaying the process of outward remodeling 
was determined by measuring the length of the internal elastic lamina (IEL). Th e intimal 
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hyperplasia was calculated by subtracting the luminal area from the area within the 
IEL. Immunohistochemical staining was performed for macrophages (MAC3, 1:200, 
BD-Pharmingen, SanDiego, USA) in a combination with CCR2 for pro-inflammatory 
phenotype (1:400, Abcam, Cambridge, UK) or CD206 (1:1000, Abcam) for anti-
inflammatory phenotype, T-lymphocytes (CD3, 1:300, Abcam) and VSMCs (αSMA, 
1:1000, Dako, Glostrup, Denmark) in a combination with Ki67 (1:200, Abcam) to 
detect proliferating cells. For the immunohistochemical analysis of the MAC3/CD206, 
MAC3/CCR2 and αSMA/Ki67 staining, the number of positive cells was counted in 3 
random fields of view using a 400x magnification from which the mean was calculated. 
Quantification of CD3+ cells was performed with ImageJ software by calculating 
% DAB positive area from the total vessel area. All immunohistochemical quantifications 
were performed on the first 3 venous sections starting from the anastomosis per AVF. 
Slides were digitized using an automated microscopic scanner (Panoramic digital MIDI, 
3DHISTECH, Hungary). Results are expressed as mean±standard error of the mean.
Cell culture
Vascular smooth muscle cells 
Primary arterial and venous vascular smooth muscle cells were isolated from 
murine carotid artery and vena cava of C57Bl/6 and RP105-/- mice (n=3 per group) 
respectively. Connective tissues were removed and vessels cut open. Endothelial 
monolayer was detached by gentle scraping with sterile surgical forceps. The carotid 
artery and caval vein were dissected into small pieces and plated onto petri dish 
100 mm or 60 mm diameter coated with 0.1 mg/ml fibronectine. After 14 days of 
culture with DMEM medium supplemented with 20% FCS, 2 mmol/l l-glutamine, 
100 U/ml penicillin and 100 µg/ml streptomycin, cells were trypsinized and re-plated 
onto 6 or 12 well plates and left for 7 days in culture. Upon enrichment in 80-90% 
confluence VSMCs were trypsinized and seeded at required density for further functional 
assays.
Macrophages
Macrophages were derived from bone marrow by flushing tibia and femur of healthy 
C57Bl/6 or RP105-/- mice (n=3 per group) and seeded at a density of 500.000 cells/
well in 6-wells plates. Cells were cultured for 7 days in RPMI GlutaMax (Gibco) 
supplemented with 100 U/ml penicillin/streptavidin, 25% Fetal Calf Serum (FCS) 
and 20 mg/ml M-CSF (Myltec Biotechnologies) as described previously6. On day 7, 
cells were stimulated either with LPS (100 ng/ml) and IFN-gamma (10 ng/ml) to 
differentiate them towards pro-inflammatory phenotype or with IL4 (10 ng/ml) and 
IL13 (10 ng/ml) (all from Preprotech) for anti-inflammatory phenotype. After 24 
hours the supernatants were collected for ELISA assays and cells were lysed with Trizol 
reagent (Invitrogen, Carlsbad, CA, USA) for RNA isolation.
VSMC proliferation assay
Murine VSMCs, explanted from aortas and veins of control or RP105-/- mice, were 
subsequently cultured as described above, and proliferation was measured using neutral 
red cell proliferation and cytotoxicity assay kit from Boster Bio (Pleasanton, CA, USA) 
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according to the manufacturer protocol (Supplementary Methods S2).
VSMC migration assay
Primary arterial and venous VSMCs from control and RP105-/- mice were grown to 
confl uence and then made quiescent in cultured medium supplemented with 1% FCS 
for 24 hours. Cells were detached from the surface using Accutase Cell Detachement 
Solution (Innovative Cell Technologies, Inc., San Diego, CA, USA) and suspended at 
a concentration of 100.000 cells/ml in culture medium supplemented with 1% FCS. 
Migration was assayed with a polycarbonate membrane inserts having 8 µm-pores 
in 24-well chemotaxis chambers using commercial CytoSelect Cell Migration Assay 
Kit (Cell Biolabs, Inc., San Diego, CA, USA) over 16 hours towards the 20% FCS 
gradient. All migratory cells were lysed and labeled with fl uorescent dye (CyQuant GR). 
Quantifi cation was performed on a fl uorescence plate reader at 480 nm/520 nm.
ELISA assays
ELISA assays for MCP1, IL6 and IL10 production were performed with cell free 
supernatant collected from bone marrow-derived macrophages after 24 hours polarization 
towards pro- or anti-infl ammatory phenotype or ex vivo cultured arterial and venous 
VSMCs using commercial available kits following the instructions of the manufacturer 
(BD Biosciences, San Jose, CA, USA: MCP1- Catalog No 555260; IL6- Catalog No 
555240, IL10- Catalog No 555252).
RT-PCR
Total RNA was extracted from the macrophages and VSMCs using Trizol reagent 
(Invitrogen) according to the manufacturer’s protocol. RNA was reverse transcribed 
using a 5-minute 65°C incubation of 1 µg total RNA with deoxyribonucleotide 
triphosphates (Invitrogen) and random primers (Invitrogen). c-DNA was synthesized 
using an M-MLV First-Strand Synthesis system (Invitrogen), and used for quantitative 
analysis of mouse genes (Supplementary Table 1) with an SYBR Green Master Mix 
(Applied Biosystems, Foster City, CA, USA). Th e relative mRNA expression levels were 
determined by normalization to murine glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) using 2[−ΔΔC(T)] method.
Statistical analysis
Results are expressed as mean±SEM and considered statistically signifi cant for p<0.05; 
T-tests and Mann-Whitney tests for parametric and nonparametric data, respectively, 
were used as appropriate. All in vitro experiments were performed in biological n=3 in 
experimental triplicates.
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Supplementary material
Supplementary Figure 1. MD2 mRNA expression levels. 
Th e relative expression normalized to GAPDH. n=3 per group.
Supplementary Figure 2. IL10 production by SMCs in vitro. 
Quantifi cation of anti-infl ammatory cytokine IL10 production by in vitro cultured SMCs isolated from 
WT and RP105-/- . No diff erence in IL10 levels was detected between RP105-/- and WT mice. n=3 per 
group.
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Supplementary Figure 3. Effects of RP105 deficiency on MCP1 expression in vivo.
Quantification of MCP+ cells in AVF lesions 14 days after surgery. No difference in MCP1+ cell number was 
detected between RP105-/- and WT mice. n=11 per group.
MATHERIAL AND METHODS
S1. Surgical procedure
The animal was anesthetized using isoflurane followed by shaving and disinfection of 
the skin in the ventral neck area and fixed in a supine position on a heating blanket. 
The mouse was then injected with buprenorphin (0.1 mg/kg) (MSD, Whitehouse 
Station, NJ, USA) and  0.5  mL saline. Under a dissecting microscope (Leica, Wetzlar, 
Germany), an incision in the ventral midline of the neck area was made, followed by 
a dissection of the right dorsomedial branch of the external jugular vein and ipsilateral 
common carotid artery after the excision of the sternocleidomastoid muscle using a 
heat cauterizer. Next, after applying a vascular clamp (S&T, Neuhausen, Switzerland) 
on the proximal and distal artery an approximate 1 mm incision was made using a 
microscissor (Fine Science Tools, Heidelberg, Germany) and the lumen was rinsed with 
a heparin solution (100 IU/ml) (LEO Pharma, Ballerup, LLDenmark). The vein was 
then clamped proximally and ligated distally, followed by a transection just proximal to 
the ligation. After rinsing the vein with a heparin solution, an end-to-side anastomosis 
was created using 10.0 interrupted sutures (BBraun, Melsungen, Germany). Halfway 
during the suturing procedure, heparin (0.2 IU/gram bodyweight) together with 200 
µL of either L-Pred (10 mg/kg bodyweight), Pred (10 mg/kg bodyweight), L-PBS or 
PBS was injected intravenously. After completion of the anastomosis, the remaining 
clamps were removed and patency was assessed. The skin was closed with a 6.0 running 
suture (BBraun, Melsungen, Germany). Following completion of the surgery 0.5 mL of 
saline was injected subcutaneously and the mice were kept warm until recovery.
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S2. VSMC proliferation assay
5x104 cells per well were seeded in 96 well plates. Next, cells were synchronized overnight 
in culture medium supplemented with 1% FCS followed by stimulation with 1ng/µl 
LPS in completed medium supplemented with 20% FCS. Absorbance of neutral red 
(C15H17IN4) by  the cells over a 16 hours period was measured by an ELISA plate 
reader at A540. Absorbance was compared between the control and knock-out animals 
with or without stimulation with LPS. All experiments were performed in biological 
triplicates.
Table 1 Primers used for in vitro experiments
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Abstract
Arteriovenous fistulas (AVFs) for hemodialysis access have a 1-year primary patency 
rate of only 60%, mainly as a result of maturation failure that is caused by insufficient 
outward remodeling and intimal hyperplasia. The exact pathophysiology remains 
unknown, but the inflammatory vascular response is thought to play an important 
role. In the present study we demonstrate that targeted liposomal delivery of 
prednisolone increases outward remodeling of the AVF in a murine model. 
Liposomes accumulate in the post-anastomotic area of the venous outflow tract in 
which the vascular pathology is most prominent in failed AVFs. On a histological 
level, we observed a reduction of lymphocytes and granulocytes in the vascular 
wall. In addition, a strong anti-inflammatory effect of liposomal prednisolone 
on macrophages was demonstrated in vitro. Therefore, treatment with liposomal 
prednisolone might be a valuable strategy to improve AVF maturation.  
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Introduction
Arteriovenous fi stulas (AVFs) are the preferred type of permanent vascular access for 
hemodialysis in view of their superior patency and lower rate of infectious complications, 
when compared to prosthetic arteriovenous grafts. However, the durability of AVFs is 
far from optimal with a 1-year primary patency of only 60%1. AVF maturation refers 
to the process of enlargement of the lumen of the access conduit and the concomitant 
increase in blood fl ow, both needed to allow safe cannulation and adequate hemodialysis 
treatment. Th e exact mechanisms underlying maturation failure are unknown, but 
impaired outward remodeling (OR) as well as intimal hyperplasia (IH) are both 
considered to contribute2. Animal studies have shown that the adaptive response 
that occurs upon AVF creation, is characterized by marked vascular infl ammation 
as illustrated by the infi ltration of macrophages and lymphocytes3,4 as well as the up 
regulation of pro-infl ammatory cytokines5. In addition, recent clinical studies suggest 
that this infl ammatory response is harmful for AVF maturation, by showing that plasma 
levels of C-reactive protein are inversely correlated with successful AVF maturation6.
Glucocorticoids (GCs) are well-known anti-infl ammatory drugs that are widely used 
for the treatment of numerous infl ammatory diseases7. Despite their excellent anti-
infl ammatory effi  cacy, the therapeutic use of systemic GCs is hampered by the high risk 
of occurrence of adverse side eff ects. Nanoparticle therapeutics such as liposomes have 
shown to facilitate selective delivery of drugs to infl amed tissues with a highly permeable 
microvasculature8, where liposomes are being phagocytized by macrophages9. 
In the present study, we evaluated the feasibility and effi  cacy of liposomal prednisolone 
(L-Pred) to target the infl amed peri-anastomotic region of murine AVFs and 
assessed its eff ect on the morphometry and composition of the venous outfl ow tract. 
Subsequently, we assessed the effi  cacy of L-Pred to reduce the infl ammatory profi le of 
cultured macrophages and evaluated its eff ect on vascular smooth muscle cell (VSMC) 
proliferation in vitro.  
Results
Surgical outcome
In total, 54 mice received an AVF (PBS; n=10, L-PBS; n=8 Pred; n=9, L-Pred; n=10, 
gold-containing PEG-liposomes; n=3), of which 14 mice (26%) did not survive the 
surgical procedure. Th e number of deaths did not diff er signifi cantly between the 
diff erent intervention groups when compared to the PBS treated group. In 6 of the 14 
mice (43%), the cause of death was clearly due to postoperative bleeding in the surgical 
area. In the rest of the cases, the cause of death was unclear.  Th e surviving mice showed 
normal behavior after recovering from the surgery until time to sacrifi ce. Figure 1, A-B 
and video 1-2 illustrate the AVF directly after surgery as well as circulating liposomes 
shortly after intravenous administration. 
With regard to adverse eff ects of systemic prednisolone phosphate therapy, animals 
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that received either liposomal prednisolone phosphate or free prednisolone phosphate 
both showed disturbed wound healing in the ears that was caused by the placement 
of earmarks at the start of the surgical procedure. However, we did not observe any 
disturbance in the wound healing of the skin incisions located in the neck and upper leg. 
Apart from this adverse effect, the general condition of all the animals remained normal 
during the study.
Figure 1. Localization of liposomes using near infrared fluoroscopy and immunohistochemistry.  
(A,B) 
In vivo imaging using NIRF of the AVF directly after creation (day 0) in mice that were injected with PBS 
(A) or L-Pred. (B) Red color overlay corresponds to the intravenously administered methylene blue visual-
ized on the 700 nm channel. Green color overlay corresponds to the intravenously administered liposomes 
that are labeled with the Alexa-750 fluorochrome visualized on the 800 nm channel. (C,D) In vivo imaging 
using NIRF of the AVF at time of sacrifice (day 14) in mice that were injected with either PBS (C) or L-Pred 
(D) at day 0, 2, 5 and 10.(*) Extravasation of liposomes in the anastomotic area of the AVF. (E) Double 
staining against F4/80 and gold particles showing accumulation of gold-labeled liposomes in macrophages 
in the venous outflow tract (black arrows). (a) Artery, (v) Vein. Bar =10 µm.
Patency
Using near infrared fluorescence (NIRF) (Figure 1, C-D and video 3-4), we observed a 
100% patency in all the groups except for the mice treated with prednisolone in which 
2 out of the 9 (22%) AVFs were occluded at time of sacrifice. This difference in patency 
was not significant when compared to PBS (P=0.15). These two occluded AVFs were 
excluded from further analysis.
Distribution of liposomes in murine AVF 
At 14 days after surgery, liposomes accumulated in the peri-anastomotic area of the 
AVF as assessed, by NIRF imaging (Figure 1D and video 4). At this time, 4 days after 
the last injection, no circulating liposomes were detected. Histological analysis of the 
venous outflow tract in mice that were injected with the gold-labeled liposomes, showed 
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Figure 2. Histological stainings of the venous outfl ow tract of the AVF at day 14 after surgery.
(A,B) Hematoxylin, phloxin and saff ron staining (HPS). (C,D) Immunohistological staining against
α -smooth muscle actin. (* ) Intimal hyperplasia, (L) Lumen, Original magnifi cation 100x. Bar = 200 µ m.
Morphometric analysis
Representative sections from the venous outfl ow tract of the AVF are shown in fi gure 
2A-B. At day 14 after surgery, the mice that were treated with L-Pred showed a 27% 
larger circumference of the external jugular vein when compared to the PBS-treated 
group (P=0.004), whereas no signifi cant diff erences were observed in the Pred-treated 
mice (P= 0.195) or L-PBS treated mice (P=0.396) (Figure 3A). 
Figure 3. Histomorphometric parameters 14 days after AVF surgery. 
(A) Venous circumference. (B) Intimal area at the venous outfl ow tract. (C) Luminal area at the venous 
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No significant differences were observed in intimal area in the experimental groups 
(L-Pred: P=0.052, Pred: P=0.350, L-PBS: P=0.494) when compared to PBS-treated 
mice (Figure 3B). Immunohistochemical staining revealed that the vast majority of the 
cells in the intima stained positive for αSMA in all the groups (Figure 2, C-D). 
The luminal area in the L-pred treated mice showed a 47% increase compared to the 
PBS treated mice (P=0.042), whereas the mice treated with Pred (P=0.766) or L-PBS 
(P=0.861) did not show a significant difference when compared to the PBS-treated mice 
(Figure 3C). 
Figure 4. Representative sections of immunohistochemical stainings against CD45 and CD3 
at 14 days after AVF surgery.
(A–D) CD45(+) cells (black arrow) in the venous outflow tract of the AVF. (E,F) CD3(+) cells (black arrow) 
in the venous outflow tract of AVF. Original magnification (A,B): 100x. Bar = 200 µm,(C–F): 400x, Bar = 
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Infl ammatory response in the AVF
Representative sections of the immunohistochemical staining against CD45 and CD3 
are shown in fi gure 4, A-F. Immunohistochemical analysis of sections obtained from the 
venous outfl ow tract revealed that the mean number of CD45(+) cells present in the 
venous outfl ow tract of the L-Pred treated mice was reduced by 83%, when compared 
to the mice treated with PBS (P<0.001). A trend towards reduction of CD45-positive 
cells in the venous vascular wall was observed in the Pred-treated mice, when compared 
to PBS (P=0.069) (Figure 5A). Additional immunohistochemical stainings for subsets 
of infl ammatory cells revealed a 86% decrease in CD3(+) T-cells (P<0.001) and a 51% 
decrease in GR1(+) granulocytes (P=0.008) in the L-Pred treated group when compared 
to the PBS treated group (Figure 5, B-D). 
Figure 5. Quantifi cation of immunohistological staining against diff erent infl ammatory cells 
at day 14.
(A) CD45(+) leukocytes. (B) F4/80(+) macrophages and F4/80(+)CD206(+) M2 macrophages. (C) 
CD3(+) granulocytes. (D) GR1(+) granulocytes in the venous outfl ow tract of AVF at day 14. (*)P < 0.05 
compared to PBS.
Infl ammatory eff ect of L-Pred in cultured macrophages 
To study  the infl ammatory eff ects on a mRNA level, we exposed murine M1 and M2 
macrophages to L-Pred, L-PBS, Pred and PBS. Upon incubation with L-Pred and Pred, 
a strong reduction was observed in the expression of pro-infl ammatory genes including 
TNF-α, MCP-1 and IL-6 (all P<0.01) by M1 polarized macrophages, whereas M2 
macrophages showed a signifi cant increase in the expression of the anti-infl ammatory 
cytokine IL-10 after addition of L-Pred and L-PBS (both P<0.01) when compared to 
the incubation with PBS (Figure 6, A-D). 
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Figure 6. mRNA expression levels of pro- and anti-inflammatory cytokines in macrophages 
in vitro after incubation with PBS (control medium), L-PBS, Pred and L-Pred. 
(A–C) Relative mRNA expression of proinflammatory cytokines (IL-6, TNF-α and MCP-1) in M1 
macrophages and (D) the anti-inflammatory cytokine IL-10 in M2 macrophages. The relative expression is 
normalized against GAPDH. (*)P < 0.05 compared to PBS.
Figure 7. mRNA expression levels of MMP-2, MMP-9 and the ratios of TIMP-2/MMP-2 
and TIMP-1/MMP-9 in macrophages after incubation with PBS (control medium), L-PBS, 
Pred and L-Pred. (A,B)
Relative mRNA expression of MMP-2 and MMP-9. (C,D) Ratios of TIMP-2/MMP-2 and TIMP-1/
MMP-9. Expression was normalized against GAPDH. (*)P < 0.05 compared to PBS.
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Eff ect of liposomal prednisolone on the expression of MMPs and TIMP. 
We measured the expression of matrix metalloproteinases (MMP-2 and MMP-9) and 
their endogenous inhibitors (TIMP-2 and TIMP-1, respectively) on RNA level in M1 
macrophages. Upon incubation with L-Pred, both MMP-2 and MMP-9 expression 
decreased when compared to PBS incubation. In addition, both the TIMP1/MMP-9 
and the TIMP2/ MMP-2 ratio increased upon incubation with L-Pred when compared 
to PBS incubation (Figure 7, A-D).
Discussion
In the present study, we demonstrate that intravenously administered liposomes 
selectively target the anastomotic region and can eff ectively improve venous outward 
remodeling of murine AVF when prednisolone is encapsulated in the liposomes. 
Liposomes are one the most prominent drug carrier systems currently available, due 
to their relative easy preparation using biocompatible components and the high 
drug payload10. Moreover, liposomes can hold their payload while circulating in the 
vasculature until they extravasate and accumulate at sites of infl ammation as a result 
of enhanced vascular permeability in infl amed tissues, thereby reducing possible 
systemic adverse side eff ects11. Th e PEG-coating of liposomes is designed to improve 
their bioavailability in infl amed tissues as it serves as a steric barrier that minimizes 
liposomal uptake by circulating mononuclear cells12. Once extravasated, the liposomes 
are recognized as foreign particles and phagocytized by macrophages10. Using NIRF 
and immunohistochemistry, we demonstrated that liposomes indeed accumulate in 
macrophages in the anastomotic area of murine AVF. Th ese results are consistent with 
previous studies in rabbits13 and humans14 which revealed marked accumulation of 
liposomes in macrophages within infl ammatory atherosclerotic plaques.  
GCs are powerful anti-infl ammatory drugs that act through binding to cytosolic 
glucocorticoid receptors in target cells, leading to a reduction in the expression of pro-
infl ammatory cytokines and diminished recruitment of infl ammatory cells15,16.  Despite 
these potent anti-infl ammatory eff ects, chronic and systemic therapeutic use of GCs is 
limited by the high incidence of serious adverse eff ects16. Moreover, as a result of rapid 
clearance from the circulation, systemic administration of GCs results in low effi  cacy 
of drug delivery at the target location. Th erefore, encapsulation of GCs in liposomal 
nanoparticles has great potential to enhance the therapeutic eff ect of GCs in infl amed 
tissues. Previous studies on L-Pred in murine model of arthritis17 have underscored this 
potential, as complete remission of the infl ammatory response was shown upon a single 
injection, which was superior to the eff ect of unencapsulated prednisolone. 
Preclinical studies have shown that GCs reduce the formation of both arterial and venous 
stenotic lesions18-20. However, the role of infl ammation in vascular remodeling upon 
AVF surgery has not been elucidated yet. Although various animal studies3-5, 21 revealed 
infi ltration of infl ammatory cells in the venous outfl ow tract in the early phase after 
AVF surgery, it is unclear whether this infl ammatory response directly contributes to 
maturation failure. Our experiments revealed that L-Pred resulted in inhibition of vascular 
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inflammation in the AVF, as illustrated by a significant reduction of lymphocytes and 
granulocytes in the venous outflow tract. Interestingly, treatment with unencapsulated 
prednisolone resulted solely in a modest reduction in inflammatory cells , suggesting 
that liposomal encapsulation indeed resulted in a higher concentration of prednisolone 
in the venous outflow tract. As shown in vitro, L-Pred induced a conversion towards 
an anti-inflammatory profile of macrophages, as demonstrated previously22. Moreover, 
liposomes themselves contribute to the reduction of the pro-inflammatory profile of 
macrophages, as illustrated by the reduction of pro-inflammatory cytokines in M1 
macrophages upon stimulation with L-PBS. This shift towards an anti-inflammatory 
profile of macrophages might have inhibited the recruitment of lymphocytes and 
granulocytes to the injured vessels of the AVF. Alternatively, prednisolone might have 
had a direct effect on lymphocytes and granulocytes as GCs can easily pass the cellular 
membrane of macrophages in both directions. 
While previous studies evaluated the therapeutic effect of GCs to inhibit IH in various 
vascular injury models18-20, none of these studies focused on its effect on vascular 
remodeling. The question arises how treatment with L-Pred resulted in enhanced 
outward remodeling in the venous outflow tract of AVF. In order to investigate whether 
L-Pred influenced VSMC proliferation and collagen production, we directly stimulated 
cultured murine VSMCs with L-Pred. However, no significant effect on VSMC 
proliferation and collagen synthesis was observed (data not shown).
MMPs are a group of proteolytic enzymes involved in vascular remodeling by facilitating 
the turnover of extracellular matrix components such as collagen and elastin23. The effect 
of MMPs on the vascular remodeling depend on the specific MMPs that are activated 
and the type of vascular injury24. Previous studies in a porcine balloon angioplasty model 
in peripheral arteries revealed that treatment with the MMP-inhibitor marimastatin 
resulted in reduced constrictive arterial remodeling in favor of expansive remodeling25. 
The exact contribution of MMPs in vascular remodeling in AVF still remains to be 
elucidated. Previous studies suggest that the effect of MMP activation on vascular 
remodeling in AVF might differ between the arterial and venous segment. Indeed, 
Castier et al. observed that enhanced MMP-9 activity coincided with increased outward 
remodeling in the arterial segment of murine AVF, whereas studies by Nieves Torres et 
al.27 revealed that MMP inhibition enhanced venous outward remodeling in AVF. In the 
latter study, adventitial delivery of a small hairpin RNA against the MMP ADAMTS-1, 
resulted in reduced macrophage infiltration, decreased MMP-9 activity and enhanced 
venous outward remodeling in murine AVF. Although we have not been able to quantify 
MMP activity in vivo, we speculate that the enhanced venous outward remodeling in 
murine AVF that occurred upon treatment with L-Pred is mediated by the dampened 
inflammatory response and decreased MMP activity in macrophages. In addition, a 
recent clinical trial evaluating the efficacy of the MMP-inhibitor doxycycline to inhibit 
growth of abdominal aortic aneurysms resulted in an unexpected acceleration of the 
aneurysmal growth26. These data suggest that in certain vascular disease conditions, 
inhibition of MMPs could enhance outward remodeling. Interestingly, elegant studies 
by Nieves Torres and coworkers27 suggest a similar effect of MMP inhibiton on venous 
outward remodeling in AVF. Indeed, adventitial delivery of a small hairpin RNA against 
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the MMP ADAMTS-1, resulted in reduced macrophage infi ltration, decreased MMP-
9 activity and enhanced outward remodeling in murine AVF. Although we have not 
been able to quantify MMP activity in vivo, we speculate that the enhanced outward 
remodeling in murine AVF that occurred upon treatment with L-Pred is mediated by 
the dampened infl ammatory response and decreased MMP activity in macrophages. 
In contrast to its eff ect on outward remodeling, no inhibitory eff ect of L-Pred on IH in 
the venous outfl ow tract was observed. Th ese results deviate from other preclinical studies 
that evaluated the therapeutic eff ect of GCs in other vascular injury models, that have 
reported a strong inhibitory eff ect of dexamethasone on IH18-20. Th is discrepancy may 
result from a diff erence in potency between prednisolone and dexamethasone to inhibit 
VSMC proliferation28. Alternatively, it may relate to the diff erence in pathophysiological 
stimuli that contribute to IH after arterial injury, when compared to venous IH in 
AVF. While hemodynamic stimuli are considered to be of vital importance for IH29,30, 
the contribution of infl ammation to IH in AVF might be limited, as suggested by our 
results. Interestingly, our study showed an increase in OR that was accompanied by a 
trend towards an increase in IH, which could potentially reduce the luminal area and 
therefore blood fl ow. Although the exact explanation for this phenomenon is not fully 
elucidated, we believe that this is due to the fact that both OR and IH are processes that 
involves VSMC proliferation. As a consequence, interventions that facilitate OR might 
therefore also result in a (modest) stimulation of IH. Of note, a stimulatory eff ect of an 
intervention on OR is more important for the ultimate luminal surface area than the 
coinciding eff ect on IH, as there is a quadratic relationship between radius and surface 
area of the vessel.
Preclinical studies in pigs4 revealed that the infl ammatory response in the venous 
outfl ow tract of AVF is temporal, peaking in the early weeks after surgery. Th is acute, 
localized infl ammatory response makes the application of L-Pred particularly appealing 
as a short-term treatment in the fi rst weeks after surgery. 
In conclusion, liposomal prednisolone reduces the local infl ammatory response and 
stimulates venous outward remodeling in murine AVF. Th erefore, treatment with 
liposomal prednisolone might be valuable strategy to reduce AVF non-maturation. Th e 
effi  cacy of liposomal prednisolone to enhance AVF maturation in ESRD patients will 
be evaluated in the LIPMAT trial  (clinicaltrial.gov ID NCT0249566), a double-blind, 
randomized, placebo-controlled trial that will commence in Q4 of 2015.
Methods
Liposomes
Prednisolone polyethylene glycol-coated (PEG)-liposomes were prepared as described 
in the supplemental data and contained 2 mg prednisolone phosphate per ml. Th e 
PEG-liposomes were labeled with Alexa 750 succinimidyl (Invitrogen, Carlsbad, CA, 
USA) and contained either prednisolone phosphate (Fagron, Capelle aan den IJssel, Th e 
Netherlands) or PBS. In order to trace the liposomes microscopically, additional PEG 
liposomes were coupled to gold particles (Nanoprobes, Yaphank, NY, USA). 
Beshaeva.indd   55 7-1-2019   13:06:54
3
Chapter 356   |
Animal experiment
The Institutional Committee for Animal Welfare at the Leiden University Medical 
Center approved all animal experiments that were performed in accordance with the 
relevant guidelines and regulations. Adult male C57bl6 mice aged 10-11 weeks were 
used for the experiments and received an unilateral AVF between the dorsomedial 
branch of the external jugular vein and the common carotid artery in an end-to-side 
manner as previously described3. At the end of the procedure, either L-Pred (10 mg/
kg bodyweight), Pred (10 mg/kg bodyweight) (Fagron), L-PBS or PBS was injected 
intravenously. The dose was determined according to the guidelines of the Food and 
Drugs Administration, in which the safe starting dose level of prednisolone was set at 
1 mg/kg. The injection volume of L-PBS and PBS was equal to the injected volume of 
the L-Pred and Pred (200 µL). Due to a positive additive effect of multiple injections 
as compared to a single injection31, we injected the mice intravenously at  day 2, 5 and 
10. In addition, 3 separate mice received a single bolus injection intravenously of gold-
labeled empty liposomes (130 µL) at day 2 to evaluate liposomal accumulation in the 
AVF microscopically. All mice were sacrificed 14 days after the surgical procedure. 
Near-infrared fluorescence imaging
To assess the accumulation of the liposomes macroscopically, we used the near infrared 
fluorescence (NIRF) imaging technique3 directly after surgery and at time of sacrifice. 
After positioning of the Fluorescence Assisted Resection and Exploration (FLARE) 
imaging system (Center for Molecular Imaging, Boston, MA, USA) approximately 46 
cm above the AVF, 200 µl 1% methylene blue (Sterop, Belgium) dissolved in saline was 
injected in the left femoral vein to assess the patency of the AVF. Video images were 
captured with 30-frames-per-second. Multiple video channels (color video, 700 nm 
and 800 nm) were obtained simultaneously with 60 milliseconds exposure times. After 
computer-controlled image acquisition, color video and NIRF images were displayed 
individually and merged in real-time. The 800 nm and 700 nm channel were used for 
imaging the liposomes and methylene blue, respectively.
Tissue harvesting and processing
Fourteen days after surgery, the mice were anesthetized (supplemental data) whereupon 
the AVF was dissected and assessed using NIRF as described above. Next, the inferior 
vena cava was transsected followed by mild pressure perfusion fixation with 4% formalin 
through an intracardiac perfusion. The tissue was processed to paraffin and 5 µm-thick 
sections of the venous outflow tract were made perpendicular to the vein with an interval 
of 150 µm. 
Morphometric analysis
Morphometric analysis was performed on Weigert’s elastin stained sections using 
quantitative imaging software (Qwin, Leica, Wetzlar, Germany). The intimal area was 
calculated by subtracting the luminal area from the area within the internal elastic 
lamina (IEL). The circumference of the vessel was determined by measuring the length 
of the IEL. Results are expressed as mean ± SEM. 
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Immunohistochemical staining and analysis
All immunohistochemical quantifi cations were performed on the fi rst 3 venous sections 
starting from the anastomosis per AVF. Slides were digitized using an automated 
microscopic scanner (Pannoramic digital MIDI slice scanner, 3DHISTECH, Hungary). 
Detailed protocols of the immunohistochemical stainings are listed in supplemental 
data. 
Serial sections from each AVF were stained with the following antibodies: anti- 
α-smooth muscle actin (αSMA) for vascular smooth muscle cells and myofi broblasts 
(Dako, Glostrup, Denmark); anti-CD45 for leukocytes (BD Pharmingen, San Diego, 
California, USA); anti-F4/80 for macrophages (Abcam, Cambridge, UK); anti-CD-206 
for anti-infl ammatory (M2) macrophages (Abcam); anti-CD-3 for T-lymphocytes 
(Abcam) and GR-1 for granulocytes (from G. Kraal, VUMC, Amsterdam, Th e 
Netherlands). To distinguish anti-infl ammatory (M2) macrophages from the whole 
macrophage population anti-F4/80 and anti-CD-206 antibodies were combined in a 
double immunofl uorescence staining.  
For the immunohistochemical analysis of the CD206-F4/80 and CD45 staining, 
the number of positive cells was counted in two random fi elds of view using a 400x 
magnifi cation from which the mean was calculated. In view of the limited presence 
of CD3+ and GR1+ cells, quantifi cation of these cells was performed by counting all 
positive cells that were present in the venous segment of the AVF. Gold-labeled liposomes 
were visualized using the LI Silver enhancement kit (Nanoprobes) and combined with 
the F4/80 staining.
Generation and stimulation of bone marrow derived macrophages
To generate bone marrow-derived macrophages (BMDM) femurs of healthy C57Bl/6 
male mice (n=3) were fl ushed with sterile PBS. Total bone marrow progenitor cells 
(BMPCs) were centrifuged at 300 g at 4 °C for 10 min and incubated for 5 min 
on ice with erythrocyte lysis buff er (Sigma-Aldrich R7757, St. Louis, MO, USA). 
After erythrocytes were depleted, remaining cells were washed three times with PBS, 
centrifuged at 300 g at 4 °C for 10 min, and resuspended in RPMI medium supplemented 
with 20% fetal calf serum (FCS), 2 mmol/L l-glutamine, 100 U/ml penicillin, 100 
µg/ml streptomycin (all from PAA, Colbe, Germany). To promote diff erentiation of 
BMPCs towards macrophages, cultured medium was supplemented with 10 ng/ml of 
macrophage colony-stimulating factor (M-CSF) (Peprotech, Rocky Hill, NJ, USA). 
Cells were seeded at a density of 1.0*106 cells per well, and the medium was replaced on 
day 3 and 5. 
On day 7, cells were stimulated either with LPS (100 ng/ml) and IFN-gamma (10 ng/
ml) to diff erentiate them towards pro-infl ammatory (M1) phenotype or with IL-4 
(10 ng/ml) and IL-13 (10 ng/ml) (all from Preprotech) for anti-infl ammatory (M2) 
phenotype. On the same day Pred (10 µg/ml), L-Pred (10 µg/ml), L-PBS or control 
medium was added to the cells (n=3). After 24 hours the supernatant was collected and 
cells were lysed for RNA isolation. 
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RNA isolation, cDNA synthesis and qPCR
Total RNA was extracted from the macrophages cells using Trizol reagent (Invitrogen, 
Carlsbad, CA, USA). RNA was reverse transcribed using a 5-minute 65°C incubation 
of 1 µg total RNA with deoxyribonucleotide triphosphates (Invitrogen) and random 
primers (Invitrogen). c-DNA was synthesized using an M-MLV First-Strand Synthesis 
system (Invitrogen), and used for quantitative analysis of mouse genes (supplemental 
data) with an SYBR Green Master Mix (Applied Biosystems, Foster City, CA, USA). 
Levels of gene expression were determined by normalization to murine glyceraldehyde 
3-phosphate dehydrogenase (GAPDH).
Statistical analysis
All data except the patency outcome were expressed as mean ± SEM. SPSS 20.0 was 
used for all statistical calculations. Except for the data on AVF patency and animal 
survival, all measurements were analyzed statistically using One-way ANOVA with 
Dunett post-hoc test with the PBS group as the reference category. A Fisher’s exact 
test was used for the data on AVF patency and animal survival. A P-value < 0.05 was 
considered statistically significant.
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Prednisolone phosphate polyethylene glycol-coated (PEG)-liposomes were prepared 
by injecting 1 mL of an alcoholic lipid solution of 1 Molar (containing dipalmitoyl 
phosphatidyl choline and dipalmitoyl phosphatidyl glycerol, both from Lipoid GmbH, 
Germany, and cholesterol (Sigma Aldrich, saint Louis, MO, USA)) in a molar percentage 
of 62%, 5%, and 33% of total lipid content, respectively), in 9 mL of an aqueous 
solution of 100 mg/ml prednisolone phosphate disodium salt (Fagron, Capelle aan den 
IJssel,Th e Netherlands). Subsequently the 10 ml crude liposome dispersion was sized by 
multiple extrusion at 60 degrees C using a medium pressure extruder (Lipex) equipped 
with two stacked polycarbonate membrane fi lters with 100 nm pores. Alcohol and free 
prednisolone phosphate (not incorporated in liposomes) were removed by ultrafi ltration 
and replacement of the fi ltrate with clean phosphate buff ered 0.9% saline (pH 7.4). Th e 
resulting formulation consisted of liposomes of approximately 105 nm in diameter as 
measured by dynamic light scattering, with a polydispersity index of 0.05 and a zeta-
potential of approximately -30 mV. Content determination was done by extraction 
using the organic phase for lipid determination (HPLC followed by evaporative light 
scattering detection) and the aqueous phase to assess the prednisolone phosphate 
content (UV spectrophotometry at 254 nm). Th e liposomes contained approximately 
2 mg prednisolone phosphate/mL and 70 µmol total lipid/ml. “Empty” liposomes 
(L-PBS) were prepared in the same manner using phosphate buff ered saline  instead of 
the aqueous prednisolone phosphate solution. 
Th e liposomes were labeled with Alexa 750 by fi rst mixing PEG(2000)-DSPE-NH2 and 
PEG(2000)-DSPE (Avanti Polar Lipids, Birmingham, AL, USA) in a 1:1 molar ratio in 
0.1 M sodium bicarbonate solution at pH 8.3. Th is mixture was then heated at 60°C 
and Alexa 750 succinimidyl (Invitrogen, Carlsbad, CA, USA) was added, which led to 
coupling of Alexa 750 to the NH2-PEGylated lipid. Th is mixture was subsequently 
added to the liposomes and mixed under repeated temperature cycling between 
60°C and room temperature, allowing the PEGylated and Alexa-conjugated lipid to 
insert in the liposome bilayer. In order to trace the liposomes at a microscopic level, 
gold-containing PEG-liposomes were prepared by adding to the PEG-liposome lipid 
mixture described above 0.1mol% dipalmitoyl phosphatidyl ethanolamine coupled to 
1.4 nm gold particles (Nanoprobes, Yaphank NY, USA). After formation of the crude 
liposome dispersion multiple extrusion was performed using the same method as with 
prednisolone phosphate PEG-liposomes and identical size characteristics were obtained 
(103 nm, polydispersity index 0.08). Th e fi nal formulation contained 10 µmol lipid/ml.
Surgical procedure
Th e animal was anesthetized using isofl urane followed by shaving and disinfection of 
the skin in the ventral neck area and fi xed in a supine position on a heating blanket. 
Th e mouse was then injected with buprenorphin (0.1 mg/kg) (MSD, Whitehouse 
Station, NJ, USA) and 0.5 mL saline. Under a dissecting microscope (Leica, Wetzlar, 
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Germany), an incision in the ventral midline of the neck area was made, followed by 
a dissection of the right dorsomedial branch of the external jugular vein and ipsilateral 
common carotid artery after the excision of the sternocleidomastoid muscle using a 
heat cauterizer. Next, after applying a vascular clamp (S&T, Neuhausen, Switzerland) 
on the proximal and distal artery an approximate 1 mm incision was made using a 
microscissor (Fine Science Tools, Heidelberg, Germany) and the lumen was rinsed with 
a heparin solution (100 IU/ml) (LEO Pharma, Ballerup, LLDenmark). The vein was 
then clamped proximally and ligated distally, followed by a transection just proximal to 
the ligation. After rinsing the vein with a heparin solution, an end-to-side anastomosis 
was created using 10.0 interrupted sutures (BBraun, Melsungen, Germany). Halfway 
during the suturing procedure, heparin (0.2 IU/gram bodyweight) together with 200 
µL of either L-Pred (10 mg/kg bodyweight), Pred (10 mg/kg bodyweight), L-PBS or 
PBS was injected intravenously. After completion of the anastomosis, the remaining 
clamps were removed and patency was assessed. The skin was closed with a 6.0 running 
suture (BBraun, Melsungen, Germany). Following completion of the surgery 0.5 mL of 
saline was injected subcutaneously and the mice were kept warm until recovery. 
Sacrification and tissue harvesting
Upon sacrifice, mice received an intraperitoneal injection with an anesthetic-mixture 
containing midazolam (5 mg/kg) (Roche, Basel, Switzerland), medetomidine (0.5 mg/
kg) (Orion, Espoo, Finland) and fentanyl (0.05 mg/kg) (Janssen, High Wycombe, UK) 
whereupon a reincision was made over the scar. The AVF was dissected and assessed using 
NIRF as described above. After a thoracotomy, the inferior vena cava was transsected 
followed by a mild pressure perfusion fixation with 4% formalin through an intracardiac 
perfusion.
Immunohistochemistry and Immunofluorescence
For immunohistochemical stainings, deparaffinization and hydration was followed by 
a treatment with 1% hydrogen peroxide and 5% bovine serum albumin in order to 
block the endogenous peroxidase and aspecific binding sites respectively. To unmask 
the antigens and epitopes antigen retrieval with Citrate Buffer (pH6) at 95-100 °C 
for 1 hour was done for CD-3, CD-206 and F4/80 antibodies. After 15 min blocking 
with 3% BSA (Sigma-Aldrich, , St. Louis, MO, USA) in PBS sections were incubated 
overnight at room temperature with specific antibodies to goat anti-mouse F4/80 
(Abcam, Cambridge, UK), rabbit anti-mouse CD-206 (Abcam, Cambridge, UK), 
rabbit anti-mouse CD-3 (Abcam, Cambridge, UK) and goat anti-mouse GR-1 (from 
G. Kraal, VUMC, Amsterdam, The Netherlands). Control sections were incubated with 
rabbit IgG at 1:200 or 1:1000 dilution for CD-3 or CD-206 respectively or goat IgG 
at 1:100 or 1:300 dilution for F4/80 or GR-1 respectively. On the next day sections 
were briefly rinsed in 1% BSA (Sigma-aldrich) in PBS and incubated for 1 hour at 
room temperature with appropriate secondary antibodies that were goat anti-rabbit IgG 
labeled with Alexa-488 or goat anti-rat IgG labelled with Alexa-568 (Molecular Probes) 
for F4/80, CD-206 double immunofluorescence staining or horseradish peroxidase 
conjugated (Jackson ImmunoResearc bh,Westgrove, PA) goat anti-rat IgG at 1:200 
dilution or peroxidase-based EnVision kit (DAKO, Glostrup, Denmark) for GR-1 
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or CD-3 respectively. For horseradish peroxidase-based stainings (CD-3 and GR-1) 
immunoreactive tissue was then developed by using a 3.3ʹ-diaminobenzidine peroxidase 
substrate kit (Dako) and counterstained with hematoxylin. For immunofl uorescence 
F4/80+/CD-206+ double staining sections were coverslipped with ProLong® Gold 
Antifade with DAPI (Life technologies, California, US) to counterstain nuclei.  All slides 
were further digitized by an automated microscopic scanner (Panoramic digital MIDI 
slice scanner, 3DHISTECH, Hungary). All histologic evaluations were performed in 
a blinded manner on the fi rst three venous sections upstream from anastomotic area. 
Venous part was chosen because most of the stenotic lesions in human AVFs occur in 
the venous outfl ow tract. For CD-3 and GR-1 immunohistochemistry the total number 
of positive cells per section was counted. F4/80 single or CD-206 double positive 
immunofl uorescence staining were quantifi ed as total number of positive cells per fi eld 
of view in x400 magnifi cation.
Table 1. Primers used for in vitro experiments
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SUPPLEMENTAL VIDEOS
Video 1-4. In vivo NIRF imaging of the AVF at day 0 and day 14 in mice treated 
with intravenously administered PBS or Alexa-750 labeled L-Pred. Th e red color overlay 
corresponds to the intravenously administered methylene blue visualized on the 700 nm 
channel. Green color overlay corresponds to the intravenously administered liposomes 
that are labeled with the Alexa-750 fl uorochrome visualized on the 800 nm channel. 
Th e animal was oriented in such a fashion that the top of the screen resembles the 
cranioventral side.  
Video 1. In vivo NIRF imaging of the AVF directly after creation (day 0) in an animal 
that was injected with PBS. Using methylene blue, we confi rmed the patency of the 
AVF. 
Video 2. In vivo NIRF imaging of the AVF directly after creation (day 0) in an animal 
that was injected with L-Pred. Intravascular circulating liposomes was confi rmed 
together with AVF patency. 
Video 3. In vivo NIRF imaging of the AVF at time of sacrifi cation in an animal that was 
injected intravenously with PBS at day 0, 2, 5 and 10. Th e neck was dissected bilaterally 
in order to expose the contralateral side. Suture threads were placed around the venous 
outfl ow tract, proximal and distal common carotid artery of the AVF and around the 
contralateral branch of the external jugular vein. AVF patency was confi rmed after 
administration of intravascular methylene blue.        
Video 4. In vivo NIRF imaging of the AVF at time of sacrifi cation in an animal that was 
injected intravenously with L-Pred at day 0, 2, 5 and 10. Suture threads were placed 
around the venous outfl ow tract, proximal and distal common carotid artery of the AVF 
and around the contralateral branch of the external jugular vein. At day 14, liposomal 
extravasation was observed around the anastomosis of the AVF and in the wound edges. 
No circulating liposomes were observed.
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Abstract
The pathophysiology of arteriovenous fistula (AVF) maturation failure is 
incompletely understood but impaired outward remodeling and intimal hyperplasia 
are considered to contribute. This adverse vascular response upon AVF surgery results 
from an interplay between vascular smooth muscle cells (VSMCs), extracellular 
matrix (ECM) and inflammatory cells. Relaxin (RLN) is a hormone exhibiting its 
action on the vasculature via interaction with its receptor (RXFP1), resulting in 
vasodilatation, ECM remodeling and decreased inflammation. In the present study, 
we evaluated the consequences of RXFP1 knockout (Rxfp1-/-) on AVF maturation in 
a murine model of AVF failure. At 14 days after AVF surgery, Rxfp1-/- mice showed a 
22% decrease in vessel size at the venous outflow tract. Furthermore, a 43% increase 
in elastin content was observed in the lesions of Rxfp1-/- mice which coincided with 
a 41% reduction in elastase activity. In addition, Rxfp1-/- mice displayed a 6-fold 
increase in CD45+ leukocytes, along with a 2-fold increase in MCP1 levels, when 
compared to WT mice. In vitro, VSMCs from Rxfp1-/- mice exhibited a synthetic 
phenotype, as illustrated by augmentation of collagen, fibronectin, TGFβ and PDGF 
mRNA. In addition, VSMCs derived from Rxfp1-/- mice showed a 5-fold increase in 
cell migration. Finally, RXFP1 and RLN expression levels were increased in human 
AVFs, as compared to unoperated cephalic veins. In conclusion, RXFP1 deficiency 
hampers elastin degradation and results in induced vascular inflammation after AVF 
surgery. These processes impair outward remodeling in murine AVF, suggesting that 
the relaxin-axis could be a potential therapeutic target to promote AVF maturation.
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Introduction
A proper functioning vascular access site is a lifeline for a lifetime for patients required 
hemodialysis. While an arteriovenous fi stula (AVF) remains the vascular access of 
choice, the frequency of primary AVF failure is approximately 40%1. Moreover, the 
primary patency rates at 1 year after creation do not exceed 60%2, making vascular 
access related complications one of the most common causes of hospitalization and 
morbidity in hemodialysis patients.
While the pathophysiology of arteriovenous fi stula maturation failure is incompletely 
understood, it is well established that both intimal hyperplasia (IH) and outward 
remodeling (OR) of the arteriovenous conduit ultimately determine luminal dimensions, 
fi stula fl ow and patency3. Several studies have shown that vascular adaptation of the 
arteriovenous conduit is characterized by an infl ammatory response that coincides with 
fl ow-mediated remodeling of the extracellular matrix (ECM) and proliferation and 
migration of vascular smooth muscle cells (VSMCs)4-11.
Relaxin (RLN) is a 6-kDa peptide hormone, originally known for its role in the growth 
and diff erentiation of the reproductive tract, and systemic hemodynamic adaptations 
during pregnancy, in particular vasodilatation12-15. Th ree relaxin genes, namely relaxin-1, 
-2, and -3 (RLN1, 2 and 3) exist in humans, whereas rats and mice have two (Rln1
and 3), with Rln1 in rats and mice corresponding to human RLN2 and representing 
the major source of circulating relaxin16. In the last 20 years, relaxin has emerged as a 
pleotropic hormone that serves critical functions irrespective of gender. Th e systemic 
eff ects mediated by RLN2 on arterial mechanical properties include increasing 
arterial compliance, reducing systemic vascular resistance, and myogenic reactivity as 
demonstrated in rats and mice12,17-20.
Furthermore, administration of recombinant RLN2 ameliorates renal and cardiac fi brosis, 
stimulates ECM turnover, and moderates infl ammation by reducing infl ammatory 
cytokines21-27.
In the context of AVF maturation, it is important to emphasize that RLN2 is expressed 
in the vessel wall28,29 and that the observed vascular eff ects of RLN2 are mediated though 
an interaction with RXFP1 (relaxin/insulin-like peptide family receptor 1, original 
abbreviation LGR7), a G-protein-coupled receptor. RXFP1 is primarily expressed on 
VSMCs and to a lesser extent on the cell surface of macrophages and endothelial cells 
of arteries and veins30-32.
In view of the emerging role of the RLN2-RXFP1 axis in vascular remodeling and 
infl ammation, we examined the consequences of disturbing this hormone-receptor 
balance in AVF maturation. For this purpose, we used the well-established murine 
AVF model in which we studied the eff ect of RXFP1 defi ciency on fi stula remodeling. 
Furthermore, we determined the eff ects of RXFP1 defi ciency on the phenotype and 
function of VSMCs in vitro.
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Material and Methods
Animals
Murine model of AVF failure
This study was performed in agreement with Dutch government guidelines and the 
Directive 2010/63/EU of the European Parliament. All animal experiments were 
approved by the Institutional Committee for Animal Welfare of Leiden University 
Medical Center and University Medical Center Utrecht. The phenotype of Rxfp1-/- 
mice was described previously33. Male wild type (WT, C57BL/6, n=10) and Rxfp1-/- 
mice (C57BL/6 background, n=10), were bred in the animal facility at the University 
Medical Center Utrecht. All animals were given water and chow ad libitum. Adult male 
mice aged 10-13 weeks were used for the experiments. AVF were created in an end-
to-side manner between the dorsomedial branch of the external jugular vein and the 
common carotid artery as previously described5,34. In short, the animal was anesthetized 
using isoflurane followed by shaving and disinfection of the skin in the ventral neck 
area and fixed in a supine position on a heating blanket. The mouse was then injected 
with buprenorphin (0.1 mg/kg) (MSD, USA) and 0.5 mL saline. Under a dissecting 
microscope (Leica, Germany), an incision in the ventral midline of the neck area was 
made, followed by a dissection of the right dorsomedial branch of the external jugular 
vein and ipsilateral common carotid artery after the excision of the sternocleidomastoid 
muscle using a heat cauterizer. Next, after applying a vascular clamp (S&T, Switzerland) 
on the proximal and distal artery an approximate 1 mm incision was made using a 
microscissor (Fine Science Tools, Germany) and the lumen was rinsed with a heparin 
solution (100 IU/ml) (LEO Pharma, Denmark). The vein was then clamped proximally 
and ligated distally, followed by a transection just proximal to the ligation. After rinsing 
the vein with a heparin solution, an end-to-side anastomosis was created using 10.0 
interrupted sutures (BBraun, Germany). After completion of the anastomosis, the 
remaining clamps were removed and patency was assessed. The skin was closed with a 
6.0 running suture (BBraun, Germany). Following completion of the surgery 0.5 mL 
of saline was injected subcutaneously and the mice were kept warm until recovery. The 
animals were sacrificed 14 days following the surgical procedure.
Blood pressure 
Systolic blood pressure was assessed with the non-invasive tail cuff system in conscious 
mice before the AVF surgery and at day 7 and 14 after an AVF was created using the 
CODA system (Kent Scientific, CT, USA). Animals were acclimated to the restrainer 
before measurements. Following the acclimation period, telemetry blood pressure 
measurements were acquired. Ten seconds data segments were collected throughout the 
duration of each noninvasive measurement session (10 acclimation cycles followed by 
20 measurement cycles).
Arterial compliance 
Aortas from Rxfp1-/- (n=3) and WT (n=5) mice were cannulated from the distal side at 
the base of the heart and proximal at the abdominal area (1 cm of length) and placed 
immediately in ice-cold HEPES buffered physiological saline solution. Consequently, 
the vessels were placed in an ex vivo vessel perfusion system containing 370C 10-4 M 
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papaverine in calcium-free HEPES buff ered physiologic saline solution. Th e vessel 
segments were tensioned to a longitudinal strain of 30 g and left to acclimatize for 15 
minutes. Th e vessel segment was then exposed to a pressurized fl ow in a cyclic fashion at 
60 BPM ± 5 BPM, where the systolic pressure was gradually increased to 120 mmHg. 
Papavarin (10-4M) in calcium-free HEPES buff ered PBS was used as perfusate. Th e 
systolic and diastolic pressures throughout the test were recorded using a pressure sensor 
(700 G Precision Pressure Test Gauge, Fluke, Singapore). To measure the vessel diameter 
a microscope camera (Digital microscope DSCO-P03, Frederiksen Scientifi c, Denmark) 
capable of measuring with an accuracy of ± 0.02 mm was placed above the perfused 
vessels. Recordings of each test was calibrated to the pressure and saved. To calculate 
arterial compliance, the vessel diameter during the systolic and diastolic phase of the 
pressure cycles, were measured. Th e dynamic compliance is provided as % compliance 
per 100 mmHg.
Tissue harvesting and processing
Fourteen days after AVF surgery, the animals were anesthetized using isofl urane. Th e 
venous and arterial limb of the AVF was dissected and a thoracotomy was performed 
whereupon the inferior vena cava was transsected followed by a fi xation with 4% 
formalin through an intracardiac perfusion. Th e tissue was embedded in paraffi  n and 5 
µm-thick sections of the venous outfl ow tract were made perpendicular to the vein at 
150 µm interval.
Morphometric and histological analysis
All (immuno)-histochemical stainings and measurements were performed on the fi rst 
3 venous cross-sections downstream from the area of anastomosis. Weigert’s elastin 
staining was used for the morphometric measurements. Th e area of the internal elastic 
lamina (IEL) was measured to assess the degree of the outward remodeling (Figure 
1a). Intimal hyperplasia was calculated by subtracting the luminal area from the area 
within the IEL. Composition of the AVF lesions was further evaluated by staining for 
total leukocytes (CD45, 1:200; BD- Pharmingen 550539, CA, USA), macrophages 
(MAC3, 1:200, BD-Pharmingen 550292, CA, USA) in a combination with CCR2 
for pro-infl ammatory phenotype (1:400, Abcam ab32144, Cambridge, UK) or 
CD206 (1:1000, Abcam ab64693, Cambridge, UK) for anti-infl ammatory phenotype, 
neutrophils (GR1, 1:300, from G. Kraal, VUMC, Th e Netherlands), T-lymphocytes 
(CD3, 1:300, Abcam ab32144, Cambridge, UK) and MCP1 (MCP1, 1:300, Santa 
Cruz sc-1784, Texas, USA) vascular smooth muscle cells (SM-α-actin, 1:1000, Dako 
M0851, CA, USA) was stained in a combination with Ki67 (1:200, BD-Pharmigen 
550609, CA, USA) to detect proliferating VSMCs.
All slides were digitized using an automated microscopic scanner (Pannoramic digital 
MIDI, 3DHISTECH, Budapest, Hungary). For the immunohistochemical analysis of 
the MAC3/CD206, MAC3/CCR2 and αSMA/Ki67 staining, the number of positive 
cells was counted in 3 random fi elds of view using a 400x magnifi cation from which 
the mean was calculated. Quantifi cation of CD45+, GR1+, CD3+ and MCP1 staining 
was performed with ImageJ software by calculating % DAB positive area from the total 
vessel area.
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Cell culture
Vascular smooth muscle cells 
Primary arterial and venous vascular smooth muscle cells were isolated from murine 
carotid artery and vena cava of C57BL/6 and Rxfp1-/- mice (n=4 per group), respectively. 
Connective tissues were removed and vessels cut open. The endothelial monolayer 
was detached by gentle scraping using sterile surgical forceps. The carotid artery and 
caval vein were dissected into small pieces and plated onto fibronectin pre-coated petri 
dishes (0.1 mg/mL) of 100 or 60 mm diameter. After 14 days of culture with DMEM 
medium supplemented with 20% fetal calf serum (FCS), 2 mM L-glutamine, 100 U/ml 
penicillin and 100 µg/ml streptomycin, cells were trypsinized and re-plated onto 6- or 
12-well plates and cultured for 7 days. At 80-90% confluence, VSMCs were trypsinized 
and seeded at required density for further functional assays.
Western Blotting
Proteins from tissue lysates were harvested in RIPA buffer and subjected to polyacrylamide 
gel electrophoresis. Protein determinations (BCA) were performed to ensure equal 
loading of protein on a per-sample basis. RXFP1 was detected using primary antibodies 
(1:500, Acris AP23446SU-S, MD, USA). GAPDH (1:5000, Cell signaling 5174S, MA, 
USA) was used as a loading control. All gels were run and blotted with Bio-Rad TGX 
pre-cast gels and blotted on nitrocellulose 0.2 µm using the Bio-Rad TurboBlot system 
(Bio-Rad Laboratories, CA, USA).
RNA isolation, cDNA synthesis and qPCR
Total RNA was extracted from VSMCs using Trizol reagent (Invitrogen, CA, USA) 
according to the manufacturer’s protocol. RNA was reverse transcribed by M-MLV 
First-Strand Synthesis system (Invitrogen, CA, USA), and used for quantitative analysis 
of mouse genes (Supplementary Table 1) with an SYBR Green Master Mix (Applied 
Biosystems, CA, USA). Murine β-actin was used as standard housekeeping gene. The 
relative mRNA expression levels were determined using 2[−ΔΔC(T)] method.
VSMC migration and haptotaxis assays
Primary arterial and venous VSMCs from control and Rxfp1-/- mice were grown to 
confluence and made quiescent in cultured medium supplemented with 1% FCS for 24 
hours. Cells were detached from the surface and suspended at a concentration of 100.000 
cells/mL in culture medium supplemented with 1% FCS. Migration was assayed with 
inserts having 8 µm-pores in 24-well chemotaxis chambers using commercial CytoSelect 
Cell Migration Assay Kit. Haptotaxis was assayed by plating cells into Transwell inserts 
with collagen I-coated inserts (CytoSelect Cell Haptotaxis Assay, Cell Biolabs, CA, USA). 
After 16 hours, migratory VSMCs were lysed and labeled with fluorescent dye according 
to the manufacturer’s instructions. 20% FCS was used as gradient. Quantification was 
performed by reading fluorescence at 480 nm/520 nm.
VSMC proliferation assay
Murine VSMCs, explanted from aortas and veins of control or Rxfp1-/- mice, were 
cultured as described above and aliquoted into a 96-well plate. All cell numbers were 
subsequently determined 24 hours later using the CyQuant Direct Cell Proliferation 
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Assay as per the manufacturer’s instructions (Life Technologies, CA, USA).
Elastase activity assay
Elastase activity was measured on total tissue lysates isolated from Rxfp1-/- and WT 
mice (n=10 per group) using the EnzChek Assay Kit (Th ermo Fisher Scientifi c, MA, 
USA) according to the manufacturer’s instructions. Briefl y, 10 µm sections of AVF were 
lysed in RIPA buff er and protein determinations (BCA) was performed to ensure equal 
loading of protein on a per-sample basis. DQ™ elastin , a soluble bovine neck ligament 
elastin labeled with BODIPY® FL dye, was used as a substrate such that the conjugate’s 
fl uorescence is quenched. In the presence of elastase, the non-fl uorescent substrate is 
digested yielding highly fl uorescent fragments which is measured with a microplate 
reader at ex/em = 480 ± 20 nm/528 ± 20 nm.
Collagen assay 
Collagen was analyzed in formaldehyde-fi xed paraffi  n-embedded venous tissues isolated 
from Rxfp1-/- and WT mice (n=10 per group) using QuickZyme Total Collagen Assay 
Kit (QuickZyme Biosciences, the Netherlands). In brief, fi ve to ten 10 µm tissue sections 
were hydrolyzed by o/n incubation at 95oC in a heat block. Upon hydrolysis, without 
any pretreatment, 35 µl was used for collagen quantifi cation using the QuickZyme 
total collagen assay (assay time 90 min). Th e assay measured the total amount of 
hydroxyproline present in the sample, which represents all collagen-types present in 
the sample. Th e assay results in a chromogen with an absorbance maximum at 570 nm.
Human tissue specimens
Human cephalic veins before AVF surgery (n=3) and during surgical revisions of AVF 
(n=3) were obtained at the Leiden University Medical Center in accordance with 
guidelines set out by the ‘Code for Proper Secondary Use of Human Tissue’ of the 
Dutch Federation of Biomedical Scientifi c Societies (Federa) and conform with the 
principles outlined in the Declaration of Helsinki. Specimens were formalin fi xed, 
embedded in paraffi  n and sectioned. Th e human AVF sections were stained with SM-α-
actin (1:1000, DAKO M0851, CA, USA), RLX2 (RLN2, 1:1000, Abcam ab183505, 
Cambridge, UK) and RXFP1 (1:4000, Acris AP23446SU-S, MD, USA).
For RXFP1 antibody validation 3 human fi stula samples were incubated with the primary 
antibody or isotype control both at 1:4000 dilution.  Human endometrium was used 
as a positive control. Briefl y, after deparaffi  nization step endogenous peroxidase was 
suppressed by incubation in 1% H2O2 for 15 min at room temperature (RT). Sections 
were then blocked with 5% PBSA (NaPO4, NaCl, NaAz and 1% bovine serum albumin) 
and 5% NHS (normal human serum) for 30min. Next, sections were incubated with the 
primary antibody or isotype control, diluted at 1:4000 in 1% PBSA buff er together with 
5% NHS, overnight at RT. After rinsing 3 × 5 min in PBS, sections were then incubated 
with rabbit Evision (Agilent Dako, CA, USA) and 5% NHS for 30min at RT. Specifi c 
signals were detected using DAB (Sigma-Aldrich, MO, USA) as chromogen, stopping 
the reaction by rapidly rinsing in tap water, followed by conventional haemalaun 
counterstaining.
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For immunofluorescent staining of double positive αSMA+, RXFP1+ cells, after primary 
antibody  sections were counterstained with Alexa 568 conjugated goat anti mouse 
IgG2a (1:250; Molecular probes A21134, MA, USA),  for SM-α-actin and Alexa 488 
conjugated secondary goat anti rabbit IgG  (1:250; Molecular probes A11008, MA, USA) 
for RXFP1. Secondary antibody were diluted in 1% PBSA and 5% NHS was added 
to prevent nonspecific binding. Nuclei were visualized with ProLong™ Gold Antifade 
Mountant with DAPI (Thermo Fisher P369, MA, USA) (Supplemental Figure 6). 
Statistical analysis 
Results are expressed as mean±SEM and considered statistically significant for P<0.05. 
T-tests and Mann-Whitney tests for parametric and nonparametric data, respectively, 
were used as appropriate. All in vitro experiments were performed in biological n=4 in 
experimental triplicates.
Results
Surgical outcome and patency
In total, 23 mice were successfully operated and received an AVF (WT; n=12, Rxfp1-/-; 
n=11), of which two (17%) from the wild-type (WT) group and one (9%) from the 
Rxfp1-/-group were occluded 14 days after surgery. The occluded AVFs were excluded 
from morphometric analysis, yielding 10 animals per group. The body weight of the 
mice was similar in both groups (29±3 gram) and remained stable until the end of 
experiment. 
Effect of RXFP1 deficiency on AVF maturation
To study the effect of RXFP1 deficiency on AVF maturation, we created AVFs in WT 
and Rxfp1-/- mice in an end-to-side fashion between the jugular vein and carotid artery 
as described previously34. Given that most of the stenotic lesions in human AVF occur 
in the venous outflow tract, we harvested the first three consecutive venous sections 
downstream of the anastomotic area for morphometric analysis. The impact of RXFP1 
deficiency on vessel morphometry was evaluated by assessing both intimal and luminal 
area as well as the area within the internal elastic lamina (IEL), reflecting the degree 
of outward remodeling of the venous outflow tract (Figure 1a). The absence of the 
RXFP1 protein in Rxfp1-/- mice was confirmed by analyzing total tissue lysates isolated 
from jugular veins by Western blotting (Figure 1b). Mice deficient for RXFP1 showed 
a 22% decrease of the IEL area at the venous outflow tract when compared to WT 
mice (P=0.002). The luminal area of the venous outflow tract in Rxfp1-/- mice was 31% 
smaller when compared to control mice, although this difference was not significant 
(P=0.14). The intimal area did not differ between groups (Figure 1c). Arterial blood 
pressure and compliance did not significantly differ between Rxfp1-/- and WT mice 
(Supplemental Figure 1).
In terms of ECM remodeling, we observed a 43% increase in elastin content in 
Rxfp1-/- mice as compared to WT mice (P=0.04) (Figure 1d), while collagen production 
was similar between the groups (Supplemental Figure 2). In both WT and Rxfp1-/- 
mice, the majority of intimal cells expressed SM-α-actin, indicating that these cells are 
primarily of VSMC or fibroblastic origin (Figure 1e).
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Figure 1. Morphometry and histology of the venous outfl ow tract of the AVF in Rxfp1-/- and 
WT mice 14 days after surgery.
(a) Th e area within the internal elastic lamina (IEL) (red), refl ects the degree of outward remodeling of the 
venous outfl ow tract. Intimal hyperplasia (green) was calculated by subtracting the luminal area (blue) from 
the area within the IEL. (b) Western blotting of the jugular vein confi rms the absence of RXFP1 protein in 
RXFP1 defi cient mice, GAPDH was used as a loading control. (c) Quantifi cation of histomorphometry. 
RXFP1 defi cient mice displayed decrease in the area of IEL (22%, P=0.002) and lumen (31%, P=0.14), 
whereas intimal hyperplasia was comparable to WT mice. (d) Increase in elastin deposition in the AVF 
lesions from Rxfp1-/- mice. (e) SM-α-actin (αSMA) staining shows area of intimal hyperplasia which did not 
diff er between the groups. Weigert elastine staining was used to determine histomorphometrical parameters 
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Figure 2. Effects of RXFP1 deficiency on inflammatory status in vivo. 
Quantification and immunohistochemical staining of (a) CD45+ leukocytes (black arrows); 
(b) MAC3+/CCR2+ macrophages, (c) MAC3+/CD206+ macrophages (white arrows), and (d) GR1+ 
neutrophils (black arrows) in the AVF lesions 14 days after surgery. All cell populations were increased in 
the lesions from Rxfp1-/- mice as compared to WT. (*) P<0.05; n=10 per group.
RXFP1 deficiency resulted in increased inflammation of AVF lesions
Immunohistochemical analysis of sections obtained from the venous outflow 
tract showed a 6-fold increase in the amount of CD45+ leukocytes in lesions of 
Rxfp1-/- mice as compared to WT mice (P=0.02) (Figure 2a). As shown in Figure 2b-c, 
further characterization of the leukocyte subpopulations revealed a 4-fold increase in the 
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in the Mac3+/CD206+ anti-infl ammatory macrophages in the lesions from Rxfp1-/- 
mice (P=0.04). Th e number of GR1+ neutrophils was 3-fold higher in Rxfp1-/- mice as 
compared to WT mice (P=0.05) (Figure 2d). Th e number of CD3+ T-lymphocytes in 
the venous outfl ow tract was not aff ected by RXFP1 defi ciency (Supplemental Figure 
3). At the level of cytokine production within the lesions, a 2-fold increase of MCP1 
expression was observed in Rxfp1-/- mice as compared to WT mice (P=0.01) (Figure 3).
In vitro, activated macrophages diff erentiated from monocytes derived from 
Rxfp1-/- mice produced similar amounts of cytokines as compared to WT mice, as ELISA 
analysis demonstrated comparable expression of MCP1, IL12 and IL10 proteins (data 
not shown).
Figure 3. Accumulation of MCP1 in the AVF lesions from Rxfp1-/- and WT mice 14 days 
after surgery. 
RXFP1 defi ciency resulted in increased MCP1 expression (brown DAB signal) as compared to WT mice. 
(*) P<0.05; n=10 per group.
Phenotypic switch of arterial and venous VSMCs upon RXFP1 deletion
Th e impact of RXFP1 defi ciency on VSMCs phenotype was studied in vitro using primary 
arterial and venous VSMCs, isolated from the aorta and caval vein of Rxfp1-/- or WT 
mice. Phenotypic diff erence of arterial and venous VSMCs was confi rmed by mRNA 
levels of ephrin B2, an established embryological marker of arterial origin35. EphrinB2 
was increased in arterial VSMCs from both WT and Rxfp1-/- mice following two weeks 
of culture as compared to venous VSMCs (Figure 4a). Further characterization of these 
VSMCs confi rmed that the cells maintained a highly diff erentiated state, as evidenced 
by the maintenance of myosin heavy chain (MHC), calponin and caldesmon expression 
at two weeks of culture (Figure 4b). 
As vascular injury and remodeling trigger the phenotypic switch of VSMCs from 
a contractile toward a synthetic state, mRNA expression levels of several genes 
associated with this switch were measured36,37. Arterial VSMCs from Rxfp1-/- mice 
expressed markedly higher levels of the synthetic VSMC markers type I collagen38 and 
fi bronectin39 as compared to VSMCs derived from WT mice (5-fold, P=0.03; 10-fold, 
P=0.04; respectively). Similarly, type I collagen and fi bronectin mRNA expression 
was augmented in venous VSMCs harvested from Rxfp1-/- mice (3-fold; P=0.05, and 
4-fold; P=0.04, respectively). Furthermore, genes linked with cellular proliferation, 
such as transforming growth factor beta (TGFβ1)40 and platelet derived growth factor 
(PDGF)41, displayed on average 3-fold higher expression levels in both arterial and 
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Figure 4. In vitro phenotypic difference between primary arterial and venous VSMCs isolated 
from Rxfp1-/- and WT mice. 
(a) Stable increase in ephrinB2 gene expression was detected in arterial VSMCs isolated from WT and 
Rxfp1-/- mice. (b) Both arterial and venous VSMCs isolated from Rxfp1-/- and WT displayed characteristics 
of mature VSMCs as confirmed by a stable expression of myosin heavy chain (MYHC), calponin and 
caldesmon genes. (c) RXFP1 deficiency resulted in a switch of arterial and venous VSMCs towards synthetic 
phenotype as confirmed by increased collagen I (Col1), fibronectine, TGFβ and PDGF mRNA expression 
levels. VSMCs were maintained in culture for14 days. (*) P<0.05; (**) P<0.005; (****) P<0.0001; n=4.
To further examine whether relaxin deficiency impacts VSMC function, we performed 
cellular migration assays. These studies revealed that arterial VSMCs derived from Rxfp1-/-
display a significantly higher migratory capacity relative to VSMCs derived from WT 
mice, while migration of venous VSMCs was unaltered (Figure 5a). To mimic VSMC 
migration within the ECM of a blood vessel, a haptotaxis assay was performed in which 
cellular migration was evaluated in a matrix of type I collagen. As shown in Figure 5b, 
we observed enhanced migration of arterial and venous VSMCs derived from Rxfp1-/- 
mice as compared to WT (5-fold, P=0.05; 5-fold; P=0.03; respectively). In contrast, 
cellular proliferation was not affected by relaxin deficiency in either arterial or venous 
VSMCs (Figure 5c). In vivo, the number of proliferating cells in the venous outflow 
tract of AVF did not differ significantly between groups (Supplemental Figure 4).
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Figure 5. Eff ect of RXFP1 defi ciency on VSMCs function in vitro. 
(a) Increase in migration of VSMCs isolated from Rxfp1-/- mice was restricted  to arterial cells only, whereas 
(b) cellular haptotaxis or migration through the layer of collagen was increased on both arterial and venous 
cells isolated from Rxfp1-/- mice. (c) Proliferation rate did not diff er between Rxfp1-/- and WT mice. Cells 
were cultured for 14 days. Migration, haptotaxis and proliferation were measured over 16h time period. (*) 
P<0.05; (**) P<0.005; n=4.
Elastin metabolism in AVF lesions of RXFP1 defi cient mice
Having observed higher elastin content in the venous outfl ow tract of AVF in Rxfp1-/- 
mice, we next assessed elastase activity in sections obtained from the venous outfl ow 
tract of the AVF. We employed the EnzChek assay, which measures fl uorescence of the 
substrate (bovine elastin) digested by elastase. Elastase activity in AVFs from Rxfp1-/- 
mice was signifi cantly reduced as compared to AVFs derived from WT mice (P=0.0001) 
(Figure 6).
Figure 6. Kinetics of the elastase activity in the lesions of Rxfp1-/- and WT mice 14 days after 
surgery. 
AVF tissue lysates from WT and Rxfp1-/- mice were incubated with DQ elastin at fi nal concentrations of 
25 µg/mL for the indicated time periods. Elastase activity in AVFs from Rxfp1-/- mice (empty triangles) was 
signifi cantly reduced after 90 and 120 min incubation time as compared to AVFs derived from WT mice 
(full circles). Fluorescence was measured in a fl uorescence multi-well plate reader set for excitation at 485 ± 
10 nm and emission detection at 530 ± 15 nm. Porcine pancreatic elastase 0.2 U/mL was used as positive 
control (full triangles). Background fl uorescence, determined for a no-enzyme control reaction, has been 
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Ex vivo, elastin synthesis in cultured arterial and venous VSMCs isolated from Rxfp1-/- 
or WT mice did not differ, as mRNA expression levels of tropoelastin were similar 
between the groups (Supplemental Figure 5).
Figure 7. Expression of RLN2 and RXFP1 proteins by αSMA+ cells in dialysis patients. 
(a) Representative images of RLN2 and RXFP1 proteins (black arrows) in human cephalic veins prior to 
AVF surgery and cephalic venous outflow tract from AVF. (b) Cells positive for RLN2 and RXFP1 (green 
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In humans RXFP1 expression increases during AVF maturation
To explore the relevance of our observations for dialysis patients, we examined three 
specimens of cephalic vein before AVF surgery and during surgical revisions of AVF. 
Immunohistochemical analysis revealed increased RLN2 and RXFP1 expression in 
the cephalic outfl ow tract of AVF, when compared to segments of cephalic veins from 
patients with end-stage renal failure during primary AVF surgery (Figure 7a). Cells that 
expressed RLN2 and RXFP1 were enriched in the intimal region of the outfl ow tract, 
and were found to co-express SM-α-actin (Figure 7b). Th ese results strongly suggest that 
RLN2 and RXFP1 expression is elevated in the venous outfl ow tract of human AVFs, 
which underscores the relevance of these proteins in the process of AVF maturation in 
humans.
Discussion
Here, we show that RXFP1 defi ciency substantially impairs outward remodeling in a 
murine model of AVF, while no eff ect on intimal hyperplasia is observed. Our fi ndings 
pinpoint an increase in elastin content in the venous outfl ow tract in RXFP1 defi cient 
mice linked with attenuated elastase activity as potentially being responsible for this 
phenotype. As such, impaired elastin degradation, in combination with enhanced 
vascular infl ammation upon AVF surgery, likely triggers adverse vascular response in 
humans following the placement of an AVF. 
Impaired elastin degradation and vascular remodeling in RXFP1 defi cient 
mice
Expansion of the venous lumen and an initial vasodilatory response are prerequisites for 
successful AVF maturation and patency. Particularly, the process of outward remodeling 
plays a pivotal role in this process. While past research focused mainly on the development 
of strategies that aimed to reduce intimal hyperplasia, current view on AVF maturation 
underscores the link between impaired outward remodeling and AVF failure42,43. To 
promote outward remodeling, matrix metalloproteinases (MMPs) expression must be 
augmented to degrade and restructure the vascular matrix44, of which elastic fi bers are a 
major component. Interestingly, peri-adventitial application of recombinant elastase has 
been shown to stimulate outward remodeling in a rabbit-model of AVF45. Interestingly, 
this concept of pharmacological elastin degradation to promote AVF maturation is now 
being evaluated in phase III clinical trials46.
Enhanced expression of relaxin is critical for ECM remodeling in the cervix and 
myometrium during pregnancy47,48. Administration of recombinant relaxin increases the 
activity of elastase in human myometrial cells26. Our discovery that RXFP1 defi ciency 
signifi cantly reduced elastase activity, resulting in elastic fi ber accumulation in AVF 
lesions suggests that RXFP1 is an important regulator of elastin degradation during 
AVF maturation. Furthermore, it supports the concept that venous outward remodeling 
requires relaxin axis-mediated augmentation of elastase activity.
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RXFP1 deficiency enhances vascular inflammation upon AVF surgery
Successful AVF maturation is severely hampered by excessive inflammation post-
surgery. Numerous animal studies have shown that drivers of inflammatory responses, 
such as heme oxygenase-1 and -2 (HO-1 and HO-2) and MCP1, are linked to AVF 
failure49-51. Within the AVF, MCP1 has been found to enhance monocyte recruitment 
and macrophage differentiation, activate endothelial cells and stimulate VSMC 
proliferation51. In one of our previous studies, local administration of liposomal 
prednisolone resulted in a reduction of the inflammatory response that resulted in a 
sharp increase in venous outward remodeling in a murine-model of AVF4. Interestingly, 
relaxin-relaxin receptor interactions are known to mitigate vascular inflammation, by 
inhibiting the upregulation of pro-inflammatory cytokines27. In keeping with these 
findings, we here found that RXFP1 deficiency augments vascular inflammation in 
AVFs, as illustrated by a significant increase in macrophage and neutrophil numbers, as 
well as accumulation of MCP1 in the venous outflow tract. 
Phenotypic switch of VSMCs from RXFP1-/- in vitro does not influence 
intimal hyperplasia in vivo. 
Despite elevated levels of MCP1 in AVF lesions of Rxfp1-/- mice we unexpectedly did not 
observe effects on venous intimal hyperplasia. To unravel this observation, in vitro studies 
on VSMCs were performed as they play a key role in intimal hyperplasia formation 
and AVF maturation. We observed that RXFP1 ablation caused a phenotypic switch 
of both arterial and venous VSMCs from a contractile towards a synthetic phenotype. 
The switch from the contractile phenotype to the synthetic, is associated with increased 
migratory and proliferative capacity. Indeed, functional studies revealed an increase 
in migration of arterial cells from Rxfp1-/- mice while migration of venous cells was 
not altered. Surprisingly, when cells had to migrate through a layer of collagen, both 
arterial and venous VSMCs isolated form Rxfp1-/- mice displayed elevated migration. 
Collectively, these findings suggest that the surrounding and ECM architecture will 
ultimately determine VSMCs behavior and could potentially differ between arterial 
and venous VSMCs. The question arises why RXFP1 deficiency in vivo resulted in 
decreased outward remodeling and had no effect on intimal hyperplasia, whereas in 
vitro functional studies clearly show impact of RXFP1 deficiency on VSMCs migration. 
In this respect, it is important to notice that the efficacy of cell migration in vivo strongly 
depends on the balance between cell deformability and ECM density, of which the latter 
is governed by the capacity of proteolytic enzymes to degrade matrix components52. 
Interestingly, RXFP1 deficiency resulted in a significant increase in elastin content as a 
result of decreased elastase activity. This preserved elastin density most likely explains 
why the increased migratory capacity of RXFP1 deficient VSMCs in vitro, did not 
translate into enhanced intima hyperplasia in the venous outflow tract of AVF in Rxfp1-/-
mice.
Alongside the well-established role for the relaxin-axis in pregnancy, the evolutionally 
conserved expression of RXFP1 within blood vessels of several mammals in a gender-
independent fashion underscores the importance of this protein-receptor interaction 
in the vasculature. Our data indicate that the RLN2 and RXFP1 proteins are highly 
expressed in human AVF lesions, strongly suggesting that therapeutic targeting of this 
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pathway in the context of AVF maturation could be benefi cial. In this respect, it is 
encouraging that clinical trials with serelaxin, a recombinant form of relaxin, have 
displayed promising eff ects in the treatment of heart failure53. In parallel, small-molecule 
agonists of RXFP1 are currently being developed54.
Despite these advances, some aspects of our study require further discussion. Our studies 
were performed in healthy mice, and given that response in animals does not necessarily 
mimic human pathology, it is critical to remain cautious in extrapolating results derived 
from murine studies to patients with chronic renal failure. Another limitation of our 
experimental setup is the inability to perform fl ow measurements and cannulations 
of the murine AVF, as an adequate blood fl ow volume and the cannulability of the 
AVF are the main characteristics of functional hemodialysis access. Nevertheless, the 
present study demonstrates the functional signifi cance of the RXFP1 pathway in AVF 
remodeling, implying that the RLN2-RXFP1 pathway could be a novel therapeutic 
target to promote maturation and longevity of AVFs for hemodialysis.
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Supplementary material
Supplementary Figure 1. (a) Arterial blood pressure levels did not diff er between Rxfp1-/- and WT mice 
over the course of AVF maturation. n=5 per group. (b) Basal arterial compliance was also similar between 
Rxfp1-/- and WT mice. n=7 WT; n=3 Rxfp1-/-.
Supplementary Figure 2. Eff ect of RXFP1 defi ciency on collagen content in vivo. 
Collagen was analyzed in venous AVF sections from Rxfp1-/- and WT mice. Total collagen content did not 
diff er between the groups. n = 10 per group.
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Supplementary Figure 3. Quantifi cation of CD3+ T-cells in the AVF lesions 14 days after 
surgery. n=10 per group.
Supplementary Figure 4. Eff ect of RXFP1 defi ciency on VSMCs proliferation in vivo. 
Quantifi cation of Ki67+/αSMA+ cells in AVF lesions of Rxfp1-/-  and WT mice 14 days after AVF surgery. 
n=11 per group.
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Supplementary Figure 5. Tropoelastine mRNA expression levels in cultured primary arterial 
and venous cells isolated from Rxfp1-/- and WT mice. n=4 per group.
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Supplementary Figure 6. Immunofluorescence RXFP1 antibody validation.  
For immunofluorescent staining of double positive SMA+, RXFP1+ cells in (a) cephalic shunt and (b) 
endometrium  after primary antibody  sections were counterstained with Alexa 568 conjugated goat anti 
mouse IgG2a (1:250; Molecular probes A21134) for SMAα and Alexa 488 conjugated secondary goat anti 
rabbit IgG  (1:250; Molecular probes A11008) for RXFP1. Mouse or rabbit IgG were used as negative 
controls. Nuclei were visualized with ProLong™ Gold Antifade Mountant with DAPI.
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Table 1. Primers used for in vitro experiments
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J.I. Rotmans, T. Bezhaeva
The battlefi eld at the 
arteriovenous crossroad:                   
invading arterial SMCs occupy the 
venous outfl ow tract of fi stulas
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Abstract 
There is an ongoing debate about the anatomical origin of the neointimal cells 
that are responsible for venous stenotic lesions in arteriovenous fistulas. Liang and 
coworkers show that vascular smooth muscle cells from the feeding artery contribute 
substantially to venous intima hyperplasia in murine AVF model. In addition, they 
show that increased Notch-signaling is the driving force behind FSP-1 mediated 
migration of these cells to the venous outflow tract.
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More than 50 years after the fi rst vascular access device for maintenance hemodialysis 
was introduced by Scribner, the options for vascular access conduits have witnessed 
substantial improvements. Currently, native arteriovenous fi stulas (AVFs) are considered 
the preferred option for vascular access in view of their lower complication rate, when 
compared to prosthetic arteriovenous grafts (AVG) and central venous catheters. 
However, AVF-related complications still constitute a major cause of morbidity for 
patients on chronic hemodialysis, as the durability of AVFs is far from optimal with 
1-year primary patency rates of 60-65%1.
Th e utility of AVFs is hampered by two distinct causes of failure: (1) initial failure to 
mature and (2) dysfunction of mature AVFs due to stenotic lesions in the venous outfl ow 
tract. Th e exact pathophysiology of both these types of AVF failure is unclear, although 
excessive intimal hyperplasia (IH) is thought to be a major cause of narrowing of the 
(venous) lumen, ultimately leading to AVF failure2. Th e vast majority of venous intimal 
cells are VSMCs and myofi broblasts, cells that both express alpha smooth muscle actin 
(α-SMA) whereas smooth muscle myosin heavy chain (SMMHC) is solely expressed by 
VSMCs. Th e stimuli responsible for the formation of IH in AVF are multifactorial and 
include hemodynamic factors such as turbulent fl ow, surgical injury as well as platelet 
activation due to repetitive cannulation. From an evolutionary point of view, veins are 
obviously not designed to cope with these excessive stimuli in AVF. To some extent, the 
outward remodeling and thickening of the intima in the venous outfl ow tract could 
therefore be considered as a physiological adaptive response that is needed to withstand 
the high hydrostatic pressure and fl ow.
Currently, there is an ongoing debate about the anatomical source of the neointimal 
cells in the venous outfl ow tract. While in the past, migrated VSMCs from the venous 
tunica media were considered to be the most prominent source of neointimal cells, more 
recent studies suggest that venous adventitial fi broblasts, circulating vascular progenitor 
cells as well as arterial VSMCs might contribute as well (Figure 1). 
In a paper in the present issue of Kidney International 3, Liang and coworkers aimed to 
further unravel the cellular origin of venous intimal cells in a murine model of AVF 
failure. In a set of complex and elegant experiments in a murine uremic model of AVF 
failure, they focused on VSMCs in the feeding artery as important contributors to 
venous IH. For this purpose, transgenic mice were used that express green-fl uorescent 
protein (GFP) in VSMCs in the carotid artery while venous VSMCs do not express 
GFP in these mice. Th is approach allowed the researchers to trace the arterial VSMCs 
in the development of venous IH in murine AVF. Histological analysis of the venous 
outfl ow tract of the murine AVFs at 2-4 weeks after surgery, revealed that half of intima 
cells in the AVF were GFP-positive and most of them expressed α-SMA, suggesting that 
VMSCs from the anastomosed artery contributed to as much as 50% of the VSMC 
compartment in the venous intima. 
Next, the researchers aimed to identify the underlying mechanisms that stimulate arterial 
VSMCs to migrate to the venous intima. Th ey hypothesized that increased Notch 
signaling could be the major driving force for arterial VSMC migration, as the Notch 
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pathway plays a critical role in vascular development, for instance by determining arterial 
versus venous vessel formation. In addition, increased Notch signaling has previously 
been associated with neointima formation4. In their previous work in the murine AVF 
model, researchers from the group led by Jizhong Cheng in Houston have already 
shown that blockade of the Notch-signaling pathway in endothelial cells prevented AVF 
failure in uremic mice5. In their present paper, Liang and colleagues confirm that Notch 
activation is increased in AVFs created in CKD mice, when compared to AVF in mice 
with normal renal function. In additional in vitro experiments, they elegantly show that 
transforming growth factor β1 (TGF-β1)-mediated upregulation of fibroblast-specific 
protein-1 (FSP-1) in VSMCs is partly dependent on the same Notch-signaling pathway. 
The latter is of particular interest since FSP-1 is an important regulator of VSMC 
migration. Subsequently, the investigators provided additional evidence for a central role 
for FSP-1 in VSMCs migration in AVF, by showing that IH was significantly reduced in 
FSP-1 knock out mice when compared to wild type mice. Finally, they evaluated human 
venous samples of failed AVFs and AVGs which revealed marked expression of both 
















































Figure 1. Schematic representation of peri-anastomotic neointima formation in AVFs
A variety of cells have been designated as contributors to IH in AVF including venous VSMCs, venous broblasts that dierentiate into myobroblasts, 
circulating vascular smooth muscle progenitor cells resident vascular progenitor cells and arterial VSMCs. With respect to the latter cells, FSP-1 mediates 
the migration towards the venous outow tract in response to Notch activation. RBP-Jκ: recombination signal binding protein for immunoglobulin 
kappa J region.
Figure 1. Schematic representation of peri-anastomotic neointima formation in AVFs.
A variety of cells have been designated as contributors to IH in A F including venous VSMCs, venous 
fibroblasts that differentiate into myobroblasts, circulating vascular smooth muscle progenitor cells resident 
vascular progenitor cells and arterial VSMCs. With respect to the latter cells, FSP-1 mediates the migration 
towards the venous outflow tract in response to Notch activation. RBP-J : recombination signal binding 
protein for immunoglobulin kappa J region.
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cells, thereby illustrating the clinical relevance of their observations in mice.
Altogether, Liang and colleagues’ fi ndings underscore the importance of the feeding 
artery as cellular source of migrating VSMCs that contribute to the formation of 
stenotic lesion in the venous outfl ow tract of AVFs. Th is observation might have 
important implications for local therapeutic strategies to inhibit IH, which thus far 
primarily focused on the draining vein as pivotal source of proliferating and migrating 
VSMCs and fi broblasts. However, one should be cautious in extrapolating promising 
results from murine studies to potential benefi t for hemodialysis patients. In general, 
the translation rate from preclinical studies to the bedside remains low, most likely 
due to diff erences in physiology and molecular pathways. In this respect, it should be 
noticed that the end-to-end confi guration that was utilized by Liang and coworkers 
for the construction of the murine AVFs, diff ers from the anatomical confi guration 
that is commonly used in humans. Indeed, AVFs in hemodialysis patients are usually 
constructed by anastomosing the end of a vein to the side of an artery. Th e exact 
confi guration is a crucial characteristic of the AVF since it determines the hemodynamic 
profi le in the AVF and aff ects blood fl ow rate, wall shear stress (WSS) levels, endothelial 
dysfunction and subsequent development of IH6. To circumvent this limitation of the 
end-to-end confi guration, we recently developed a novel murine AVF model with a 
confi guration similar to the one used most frequently in humans7. In addition, we 
should keep in mind that the geometrical orientation of the arterial and venous parts 
of the AVF in the described end-to-end model diff ers from an end-to-side anastomosis. 
Indeed, arterial VSMCs can relatively easily migrate towards the venous segment in the 
end-to-end confi guration, whereas in the end-to-side model, the anatomical distance 
between the arterial segment and especially the cushioning region of the vein (see Figure 
1) is larger. Interestingly, previous studies that were performed using an end-to-side 
confi guration in rats, failed to demonstrate a substantial contribution of arterial VSMCs 
to venous IH in AVF8. As Liang and coworkers primarily focused on peri-anastomotic 
IH, the contribution of arterial VSMCs in more downstream stenotic lesions as well as 
in venous lesion of AVGs, remains to be determined. Future studies should reveal if the 
arterial VSMCs indeed have the capacity to make such long-distance trips. 
Th e question arises how the presented data on the Notch/FSP-1 signaling in arterial 
VSMCs could translate into novel therapeutic approaches to improve AVF patency. 
An interesting option would be to evaluate the effi  cacy of Notch-inhibitors that have 
been developed in the fi eld of oncology. Th ese small-molecules could be applied to the 
arterial adventitia during AVF surgery, for instance using a hydrogel-based local delivery 
system that facilitates sustained release of the compound. In this respect, it is important 
to recognize that complete inhibition of VSMC proliferation and migration in the early 
phase after AVF surgery do not necessarily translate into a better functional outcome of 
AVFs, as (limited) VSMC proliferation might be a prerequisite for adequate outward 
remodeling of the involved blood vessels9. Th erefore, the timing of the application of 
novel interventions to inhibit VSMC proliferation could be crucial for its eff ect on the 
functional outcome of the AVF. 
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Nevertheless, the latter complicating issues should not distract from the fact that these 
mechanistic studies on the pathophysiology of AVF failure open up a new perspective on 
potential therapeutic strategies, aimed to modulate the suboptimal vascular response in 
AVFs for hemodialysis access. Liang and coworkers should be congratulated which their 
excellent work which hopefully can be translated into local interventions that improve 
the performance of this ‘lifeline’ of hemodialysis patients.
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Abstract 
Tissue engineered blood vessels (TEBVs) hold great promise for clinical use 
in patients with end stage renal disease (ESRD) requiring vascular access for 
hemodialysis. A promising way to make TEBVs is to exploit foreign body response 
(FBR) of polymeric rods used as templates. However, since the FBR predominantly 
involves bone-marrow (BM) derived cells and ESRD coincides with impaired 
function of BM, it is important to assess the generation of TEBVs in conditions 
of renal failure. To this end, we implanted polymer rods in the subcutis of rats 
after BM-transplantation with GFP-labeled BM cells in a model of chronic kidney 
disease (CKD). At 3 weeks after implantation, rods were encapsulated by tissue 
capsule (TC) composed of collagen, myofibroblasts and macrophages. On average, 
13% of CD68+ macrophages were GFP+, indicating BM origin. Macrophage-to-
myofibroblasts differentiation appeared to play an important role in TC formation 
as 26% of SMA+/GFP+ myofibroblasts co-expressed the macrophage marker 
CD68. Three weeks after rod implantation, the cellular response changed towards 
tissue repair, characterized by 40% increase in CD68+/CD163+ repair associated 
macrophages and 95% increase in TGFβ and IL10 gene expression as compared 
to TCs harvested at 1 week. These results show that both BM derived and tissue 
resident cells, contribute to TC formation, whereas macrophages serve as precursors 
of myofibroblasts in mature TCs. Finally, the presence of CKD did not significantly 
alter the process of TC formation, which holds the potential to support our 
approach for future clinical use in ESRD patients. 
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Introduction
Patients with cardiovascular disease (CVD) or end-stage renal disease (ESRD) frequently 
require surgery to either replace diseased blood vessels or create a vascular access site for 
hemodialysis1-3. For this purpose, native veins are generally preferred due to superior 
patency rates when compared to prosthetic grafts, but often unavailable due to preexisting 
vascular pathology4,5. The failure of synthetic vascular grafts predominantly results from 
the development of intimal hyperplasia ultimately leading to graft occlusion, and a 
relatively high risk of infectious complications6-8. In recent years, various strategies to 
create tissue engineered vascular grafts have been developed in an effort to overcome 
current limitations of synthetic grafts and diseased native blood vessels9-11. Indeed, tissue 
engineered blood vessels (TEBVs) can be tailor-made, do not have inconvenient valves 
and side-branches, are free from pre-existing vascular diseases and have the potential to 
adapt to changing hemodynamic conditions. 
Our approach to generate autologous TEBVs in vivo is based on the foreign body 
response (FBR) directed to a subcutaneously implanted polymer rod that culminates 
in the formation of a fibrocellular tissue capsule (TC), that encapsulating the rod12. 
Upon extraction of the polymer rod several weeks after implantation, the remaining TC 
is grafted into the vasculature, whereupon it differentiates into a blood vessel. In this 
approach, the subcutaneous space is utilized as an in situ bioreactor to grow a completely 
autologous blood vessel. In a previous study in pigs, we demonstrated that upon vascular 
grafting, the TCs phenotypically differentiate towards a blood vessel, as demonstrated 
by enhanced matrix synthesis, differentiation of fibroblasts toward contractile vascular 
smooth muscle cells (VSMCs) and endothelialization of the luminal surface13. 
The dynamics of the FBR to implanted materials have been elucidated in detail14. The 
early phase of the FBR is characterized by the recruitment of inflammatory cells, which 
is followed by the formation of granulation tissue, ultimately resulting in a fibrocellular 
TC, which completely encapsulates the implanted foreign body15. However, the origin 
of the cells present within the TCs is still unknown. Understanding the origin of cells 
present in the TC is of vital importance for its application as vascular grafts, as various 
disease conditions such as diabetes mellitus, chronic kidney disease (CKD) and ischemic 
peripheral arterial disease coincide with impaired function of bone marrow (BM)-
derived cells16-18, which could hamper TC formation.
In the present study, we aimed to elucidate the contribution of BM-derived cells in 
TC formation in a rat model of green fluorescent protein (GFP) BM transplantation19. 




All the animal work was performed at the University of California, Los Angeles and 
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approved by the institutional animal care and use committee. Five-weeks old male 
Sprague Dawley (SD) rats (200-250 g) were purchased from Jackson Laboratory 
(USA) (n=27),  transgenic enhanced GFP SD rats (SD-Tg(UBC-EGFP)2BalRrrc) were 
purchased from rat resource and resource center (University of Missouri, Columbia, 
USA) (n=9). All animals were housed in the local facilities accredited by the American 
Association for Accreditation of Laboratory Animal Care and were maintained under 
controlled conditions of light, temperature, and humidity.
Bone marrow transplantation
After 1-week acclimatization to the new environment, SD-Tg(UBC-EGFP)2BalRrrc 
rats were used as donor rats for the extraction of bone marrow cells (BMCs). BMCs were 
harvested from the femurs and tibias of 6 to 8-weeks-old SD-Tg(UBC-EGFP)2BalRrrc 
rats and the nucleated cells were enriched by lysing red blood cells with Red blood cell 
lysis buff er (1.2 mL, Sigma, St Louis, MO, USA). Th e recipient SD rats were lethally 
irradiated with two apart doses of 5.5 Gy each (11 Gy in total) with a 4h brake using 
a cobalt-60 gamma source. BMCs (2*107) were injected via tail vein into recipient rats 
24 hours after irradiation. To prevent infections after BM transplantation antibiotic 
sulfamethoxazole and trimethoprim (0.5 mg/kg) was administrated via the drinking 
water for 12 days post transplantation. Th ree weeks after BM reconstitution peripheral 
blood (0.2 mL) was collected from the tail vein to determine enrichment in GFP+ cells 
by fl uorescence-activated cell sorting (FACS) analysis. 
Model of chronic kidney disease
All operations were performed under isofl urane anesthesia. Th ree weeks after BM 
transplantation rats were randomly divided into two experimental groups: healthy 
controls (n=10) and rats with CKD (n=17). CKD was induced by two-stage subtotal 
nephrectomy (uninephrectomy of left kidney (UNX) followed 7 days later by 2/3 removal 
of right kidney), as described previously20,21. Two weeks later CKD was confi rmed by 
measuring serum creatinine and blood urea nitrogen (BUN). 
Implant material
Solid cylindrical-shaped rods composed of the elastomeric co-polymer PEOT/PBT 
of 1.75 – 0.25 mm in diameter and 1.5 cm in length were fabricated with a rapid 
prototyping unit33 (Envisiontec GmbH, Gladbeck, Germany) used as melt extruder. 
Rods were composed of the co-polymer poly(ethylene oxide terephthalate)epoly(butylene 
terephthalate) (PEOT/PBT, Polyvation, Th e Netherlands), with a PEOT/PBT weight 
percentage of 55/45 and 300 g/mol molecular weight of the initial polyethylene glycol 
used for the copolymer reaction. Th e implant surface was modifi ed by etching with 
chloroform as previously described12,22. Surface topography of all modifi ed rods was 
evaluated using scanning electron microscopy (SEM). Rods were sterilized by gamma 
irradiation at a minimum dose of 25 kGy (Synergy Health Ede, the Netherlands). 
Th e eff ect of gamma-radiation on the surface was evaluated using scanning electron 
microscopy (SEM).
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Implantation of polymeric rods
Per rat, four rods were implanted in the subcutaneous space of the abdominal area. 
First pair of rods were inserted at 2 weeks after CKD induction and 5 weeks after BM 
transplantation, and left in place for 3 weeks. One week before rods extrusion another 
pair of rods were inserted for 1-week time point. Following a small horizontal incision of 
ca. 0.5 cm, a longitudinal subcutaneous pocket was formed where the rods were inserted. 
The incision was closed using 4-0 vicryl sutures (Johnson & Johnson, NJ, USA). The 
skin was closed intracutaneously. Rats directly received post operational analgesia via 
pre-operative injection of buprenorphine (0.01-0.05 mg/kg) and 2 oz gel cups with 
Carprofen (5 mg/kg) were placed into the cages for up to 3 days post-surgery. One or 
three weeks after insertion of the rods, tissue capsules were harvested and animals were 
euthanized by CO2 asphyxiation. In short, a longitudinal incision lateral to the rod 
was made and the tissue capsule was gently removed from the surrounding tissue. After 
harvesting, rods could easily be extruded from the tissue capsule. 
Morphometric and histological analysis
Tissue capsules containing rods were fixed in 4% paraformaldehyde. After extrusion of 
the rods, tissue capsules were processed and embedded in paraffin. Serial cross sections 
of 5 mm of two parts of each tissue capsule were made for immunohistochemical and 
immunofluorescence analysis. To characterize the extracellular matrix, serial sections 
of each tissue capsule were stained with picrosirius red for collagen and Movat’s stain 
for other extracellular matrix (ECM) components. Total collagen content was analyzed 
using QuickZyme Total Collagen Assay Kit (Biosciences, the Netherlands) according to 
the manufacturer protocol. In brief, five to ten 10 µm tissue sections were hydrolyzed 
by o/n incubation at 95oC in a heat block. Upon hydrolysis, 35 µl was used for collagen 
quantification. The assay measured the total amount of hydroxyproline present in the 
sample after 90 min of incubation time, which represents all collagen-types present in 
the sample. The assay results in a chromogen with an absorbance maximum at 570 nm.
Cellular composition of tissue capsules was characterized using immunohistochemistry, 
with antibodies against a-smooth muscle actin (1:1000; Dako M0851, CA, USA) for 
myofibroblasts, CD68 (1:300; Abcam Ab31630, Cambridge, UK) for macrophages and 
Ki67 (1:100; BD-Pharmigen 550609, CA, USA) for proliferating cells and visualized 
with 3.3¢-diaminobenzadine (DAB). 
To visualize GFP+ cells sections were stained with anti-GFP antibody (1:100; Abcam, 
ab13970, Cambridge, UK) with secondary Cy5 conjugated Goat anti-Chk IgY (1:500; 
Abcam ab97147, Cambridge, UK). For immunofluorescent staining of CD68 after 
primary antibody Alexa 568 conjugated goat anti mouse IgG1 (1:300; Molecular Probes 
A21124, OR, USA) was used. SMA was counterstained with Alexa 488 conjugated 
secondary mouse IgG2a (1:250; Molecular Probes A21131, OR, USA). Stem/
progenitor cell-like population was stained with CD133 (primary ab 1:200; Abcam 
Ab19898, Cambridge, UK) and secondary goat anti rabbit IgG Alexa 488 (1:250; 
Molecular Probes A11008, OR, USA). Anti-inflammatory macrophages were visualized 
by the double staining of CD68 and CD163 (1:400; Immunologic 1105-C01, the 
Netherlands; secondary goat anti rabbit IgG Alexa 488 (1:250; Molecular Probes 
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A11008, OR, USA). Nuclei were visualized with ProLong™ Gold Antifade Mountant 
with DAPI (Th ermo Fisher P369, MA, USA). Negative controls were obtained using 
an isotype antibody and in addition for all stainings a positive control was taken along.
All slides were digitized using an automated microscopic scanner (Pannoramic 
digital MIDI, 3DHISTECH, Budapest, Hungary). For the quantifi cation of 
all immunofl uorescence staining, the number of positive cells was counted in 8 
random fi elds of view within the TC area at 60x (CD68+ and CD68+/GFP+) or 120x 
(SMA+/GFP+; SMA+/GFP+/CD68+; CD68+/CD163+ and CD133+/GFP+/SMA+) 
magnifi cation, from which the mean was calculated. Quantifi cation of bright fi eld Ki67 
staining was performed with HistoQuant software (3DHISTECH) by calculating % 
DAB positive area from the total tissue capsule area.  
Flow Cytometry and Blood and BM Analysis
Th e peripheral blood was withdrawn from rat tail vein into tubes containing 15% 
EDTA for FACS analysis. For the analysis of GFP+ cells in the BM, complete BM was 
fl ushed out from femurs and tibia of rats post-lethality. Red blood cell lysis buff er (1.2 
mL, Sigma, St Louis, MO, USA) was added into the tubes containing 0.1 mL blood 
and/or BM and incubated at 370C for 5 minutes followed by addition of 10 mL PBS 
and centrifugation to remove the lysed red blood cells. Th e cells (106 cells/mL) were 
resuspended in 50 mL FACS buff er (PBS containing 1% BSA and 0.01% sodium azide) 
and incubated with Hoechst antibodies (Th ermo Fisher, MA, USA) for life/dead cell 
gating. GFP fl uorescence on the surface was determined by fl uorescence-activated cell 
sorting analysis (FACS, LSR II; BD Biosciences, CA, USA). Data were analyzed using 
FACS-Diva software (BD Biosciences, CA, USA). 
RNA isolation, cDNA synthesis and qPCR
Total RNA was extracted from VSMCs using Trizol reagent (Invitrogen, CA, USA) 
according to the manufacturer’s protocol. RNA was reverse transcribed by M-MLV First-
Strand Synthesis system (Invitrogen, CA, USA), and used for quantitative analysis of rat 
genes (Supplementary Table 1) with an SYBR Green Master Mix (Applied Biosystems, 
CA, USA). Ribosomal protein S15 (RPS15) was used as standard housekeeping gene. 
Th e relative mRNA expression levels were determined using 2[−ΔΔC(T)] method.
Statistical analysis 
Results are expressed as mean±SEM and considered statistically signifi cant for P<0.05. 
T tests and Mann-Whitney tests for parametric and nonparametric data, respectively, 
were used as appropriate. 
Beshaeva.indd   107 7-1-2019   13:17:26
6
Chapter 6      |108         
Results
Surgical procedure
Generation of rats with GFP-labeled hematopoietic cells and chronic kidney disease  
To investigate the contribution of BM derived cells to TC formation, we established 
a rat model where cells of the hematopoietic lineage expressed GFP. SD rats were 
transplanted with BM cells derived from transgenic GFP-SD rats. No immunological 
rejection occurred, as all of the experimental animals underwent BM-transplantation 
survived and demonstrated high engraftment of donor-derived GFP+ cells. Percentage of 
GFP+ cells was evaluated by FACS analysis of the peripheral blood at three time points: 
1) 3 weeks after BM transplantation; 2) 6 weeks later, when the polymeric rods were 
implanted; and 3) when the polymeric rods were excised from the TC, another 3 weeks 
later. The percentages of GFP+ BMCs in the peripheral blood of the rats at these 3 time 
points were 74±1.6%; 80±1.5%; and 77±3%, respectively. The percentage of GFP+ cells 
in the BM at time of TC harvest was 72±3.6%.
Three weeks after BM transplantation, 17 rats underwent a 5/6 nephrectomy procedure 
from which 8 rats survived (47%). The healthy control group (WT) comprised of 10 
animals with BM transplant but without the 5/6 nephrectomy procedure. 
The CKD condition was established and persisted for the duration of TC formation. 
At the time of TC harvest, histological analysis of the remaining kidney of CKD rats 
revealed enlarged sclerotic glomeruli, dilated tubuli, regions of tubular necrosis and 
cast formation (Supplementary Figure 1). These structural changes coincided with 
elevated serum creatinine and BUN levels at the time of rod implantation and rod 
extrusion (mean creatinine levels: implantation—WT 0.4 mg/dL, vs. CKD 0.94 mg/
dL, P=0.0001; extrusion—WT 0.48 mg/dL vs. CKD 1.1 mg/dL P=0.0001; mean BUN 
levels: implantation—WT 15.2 mg/dL vs. CKD 31.1 mg/dL, P=0.0007; extrusion—
WT 18.6 mg/dL vs. CKD 40.25 mg/dL, P=0.0005). 
The high mortality rate (53%) of CKD animals was primarily due to uremia as creatinine 
and blood urea nitrogen levels in these animals were very high, emphasizing the severity 
of 5/6 nephrectomy model (data not shown).
Implantation of the rods and TC harvest
Fabrication of implanted material was performed as previously described12. To 
create a homogeneous porous surface along the rod, for optimal inflammatory cell 
recruitment and organization of collagen and myofibroblasts, rods were etched 
with chloroform. Chloroform etching was verified using SEM (Supplementary 
Figure 2). 
Two weeks after induction of CKD, 4 polymer rods were implanted into the 
subcutis of the rats in the abdominal area. TCs were harvested at 1- and 3-weeks 
after subcutaneous implantation of the rods. The study design is summarized in 
figure 1.
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Figure 1. Schematic representation of the project work fl ow. 
(1) 2*107 of total bone marrow cells harvested from transgenic Sprague Dawley (SD) rats ubiquitously 
expressing green fl uorescent protein (GFP) were injected into the tail vein of wild-type (WT) SD recipient 
rats; n=27. Th ree weeks after the bone marrow reconstitution percentage of GFP+ cells in the peripheral 
blood of recipient rats was measured by FACS analysis. (2) 2-step induction of chronic kidney disease 
(CKD); 1) unilateral right side nephrectomy and 2) 2/3 subtotal nephrectomy of the left kidney. Degree of 
CKD was confi rmed by serum creatinine and blood urea nitrogen (BUN) levels 2 weeks after the procedure. 
(3) Polymeric rods were implanted into subcutaneous space of CKD and WT animals. (4) After 1 and 3 
weeks implantation, rods together with formed fi brocellular tissue capsule were extruded and processed for 
further analysis. n=10 WT, n=8 CKD group.
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Tissue capsule formation
Cellular organization within the TC gradually changed from a disorganized, highly 
nucleated structure at 1-week, to circumferentially aligned tissue at 3-weeks in both 
WT and CKD groups. TCs were mainly composed of extracellular matrix components 
(Figure 2a) and SMA+ myofibroblasts (Figure 2b). The evolution of the TC formation 
was characterized by an initial accumulation of CD68+ macrophages in proximity to the 
synthetic rod at the 1-week time point, whereas at 3-weeks CD68+ cells were gradually 
dispersed through the entire TC volume (Figure 2c).  Furthermore, the number of 
Ki67+ proliferating cells at 3-weeks reduced by 40% and 67% (P=0.03) in WT and 
CKD animals, respectively, when compared to the 1-week time point (Figure 2d). 
The collagen density gradually increased as the TC maturated, forming a well-defined 
circular structure at 3-weeks in both WT and CKD animals (Figure 3a). Analysis of 
the total collagen content revealed increase in total collagen amount in the TCs at 3 
weeks in both WT and CKD animals (WT: 54% increase, P=0.02; CKD: 61% increase, 
P=0.01) when compared to TCs obtained at 1 week after rod implantation (Figure 
3b). No difference in collagen content was detected between WT and CKD animals, 
indicating that CKD state has no major influence on collagen synthesis in the TCs. 
Figure 2. Cellular composition of tissue capsule at 1 and 3 weeks post-implantation. 
Immunohistochemical staining of (a) various constituents of connective tissues by MOVAT; (b) SMA+ 
myofibroblasts, (c) CD68+ macrophages and (d) Ki67+ proliferating cells in the TC from healthy controls 
(WT) and chronic kidney disease (CKD) rats harvested at 1 and 3 weeks post-implantation. n=10 WT, 
n=8 CKD group.
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Figure 3. Changes in collagen content over the time course of tissue capsule maturation. 
(a) Picrosirius red staining of the collagen. Th e collagen density gradually increased forming a well-defi ned 
circular structure at 3 weeks in both WT and CKD animals. (b) Analysis of the total collagen amount 
measured by QuickZyme Total Collagen Assay Kit. Signifi cant increase in collagen content within WT and 
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A minority of inflammatory cells within TCs originates from the bone 
marrow 
The number of CD68+ macrophages in the TCs at 3-weeks increased by 28% (P=0.03) 
and 82% (P=0.0006) in WT and CKD animals respectively, as compared to 1-week 
(Figure 4a,b). 
Figure 4. Macrophages in tissue capsule formation. 
(a) Immunofluorescence staining of CD68+ macrophage marker (red color) and bone marrow derived GFP 
marker (light blue color). CD68+/GFP+ bone marrow derived macrophages (white arrows) was detected in 
the TC harvested at 1 and 3 weeks in WT and CKD group. (b) Quantification of total CD68+ macrophages 
within TC harvested at 1 and 3 weeks in WT and CKD animals. (c) Quantification of CD68+/GFP+ bone 
marrow derived macrophages from total CD68+ population. Nuclei DAPI (blue color). (*) P<0.05; (***) 
P<0.001; n=10 WT, n=8 CKD group.
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Analysis of CD68+/GFP+ cells within TC at 1-week revealed that 11.2±1% and 16.9±2% 
of CD68+ cells originated from the bone marrow in WT and CKD group, respectively 
(Figure 4a,c). Th e percentage of BM-derived CD68+/GFP+ macrophages in TC at 
3-weeks was 15.4±2% and 11.3±1.3% in WT and CKD group, respectively (Figure 
4a,c). At 1-week time point, the percentage of CD68+ cells that expressed GFP was 
1.5 times higher in the CKD group as compared to WT animals (P=0.03), whereas at 
3-weeks this trend reversed (Figure 4c). Th e percentage of CD68+/GFP+ cells, from the 
CKD group, detected in the TC harvested at 3-weeks, was reduced by 33% as compared 
to the 1-week time point (P=0.02), (Figure 4c). 
Contribution of bone marrow derived cells to myofi broblasts population in 
mature TCs
As described above, the TC harvested at 3-weeks was characterized by an increase in 
SMA+ myofi broblasts and accumulation of collagen and as compared to TCs obtained at 
1-week after rod implantation (Figure 2b; 3a,b). Analysis of the TC harvested at 3-weeks 
revealed that 36% and 35% of SMA+ cells were originating from the BM as they were 
positive for GFP in WT and CKD group, respectively (Figure 5a,b). Moreover, 29% 
and 23% of SMA+/GFP+ myofi broblasts co-expressed a macrophage marker CD68 in 
the WT and CKD group, respectively (Figure 5a,c), suggesting a role for macrophage to 
myofi broblasts transition in TC formation. 
Figure 5. Macrophage to myofi broblasts transition. 
(a) Immunofl uorescence staining of SMA+ myofi broblasts (green color) co-expressing bone marrow derived 
GFP marker (light blue color) and CD68+ macrophage marker (red color). Population of SMA+/GFP+/
CD68+ myofi broblasts (white arrows) was detected in TC at 3 weeks in both groups. Quantifi cation of (b) 
SMA+/GFP+ and (c)  SMA+/GFP+/CD68+ myofi broblasts from total SMA+ population within TC harvested 
at 3 weeks in WT and CKD group. Nuclei DAPI (blue color). n=9 WT, n=8 CKD group.
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Tissue-resident macrophages in TC formation 
There is accumulating evidence that tissue-resident macrophages orchestrate tissue-
repair responses23. Immunohistochemical analysis of the TCs obtained at 3 weeks after 
rod implantation revealed that 53% and 58% of CD68+ macrophages expressed the 
anti-inflammatory marker CD163+, in WT and CKD animals respectively (Figure 
6a,b). Gene expression analysis confirmed the repair-associated phenotype of these cells, 
as mRNA levels of transforming growth factor beta (TGFβ) in WT group was elevated 
by 2-fold (P=0.03), whereas mRNA levels of the anti-inflammatory cytokine IL10 in 
CKD group was 2-fold higher (P=0.04) in the TCs harvested at 3-weeks as compared to 
1-week time point (Figure 6b).
Discrete population of cells positive for stem/progenitor-cell marker CD133 
We observed a population of GFP+/CD68- cells that accumulated predominantly at the 
outside border of the TC (Supplementary Figure 3). Interestingly, nearly all of these 
GFP+/CD68- cells expressed CD133, a marker of progenitor cells of various origin24, in 
both WT and CKD animals. Moreover, 24% of the CD133+/GFP+ cells co-expressed 
SMA (Figure 7a, b) indicating that BM derived hematopoietic stem cells can serve as 
direct precursors to myofibroblasts in mature TCs.  
Figure 6. Tissue resident macrophages in tissue capsule formation. 
(a) Immunofluorescence staining of CD68+ macrophages (red color) positive for tissue resident marker 
CD163 (green color). (b) Quantification of the CD68+/CD163+ tissue resident macrophages from 
total CD68+ cells. (c)  Gene expression analysis of transforming growth factor beta (TGFβ) and anti-
inflammatory cytokine IL10 in the TC at 1 and 3 weeks in WT and CKD group. Nuclei DAPI (blue color). 
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Discussion 
In the present study, we showed that both BM-derived and tissue-resident cells contribute 
to TC formation upon subcutaneous polymeric rod implantation. Surprisingly, only 
13% of the macrophages within the TC originated from the BM, whereas 36% of 
the myofi broblast originated from BM precursors. A substantial number of SMA+
bone marrow derived myofi broblasts co-expressed CD68, highlighting the role of 
the macrophage-to-myofi broblast transition in the formation of the TC. During the 
maturation of the TC, the cellular response predominantly displayed repair associated 
characteristics. Importantly, the CKD condition did not signifi cantly aff ect the process 
of TC formation. 
Figure 7. Expression of CD133 and GFP proteins by SMA+ myofi broblasts in TC.
(a) Immunofl uorescence staining of SMA+ myofi broblasts (green color) originating from GFP+ bone 
marrow (light blue color) derived CD133+ stem/progenitor-cells (red color). CD133+/GFP+/SMA+ cells 
(white arrows) were detected in the TC at 3 weeks in both experimental groups detected. (b) Quantifi cation 
of CD133+/GFP+/SMA+ within the TC at 3weeks in WT and CKD group. DAPI-nuclei blue. n=10 WT, 
n=8 CKD group.
Tissue-resident and BM-derived cells both contribute to the infl ammatory response upon 
polymer rod implantation
Several studies have shown that the encapsulation of the foreign body is initiated with 
an infl ammatory response, mainly through the activity of macrophages14,15,25-27. In this 
study, we also observed that along the inner border – adjacent to the polymeric rod – 
the tissue capsules were mainly composed of CD68+ macrophages. Remarkably, only 
a minority of the macrophages within the TC originated from the bone marrow, as 
only 13% of the total CD68+ population co-expressed GFP. Several studies suggest 
that cells within the local tissue environment, such as tissue-resident macrophages, 
also contribute to the foreign body response and play major role in the formation of 
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engineered tissue28-30. Tissue-resident macrophages consist of a mixture of embryonic- 
and adult-hematopoietic stem cell-derived macrophages, which have the capacity to 
self-renewal throughout adulthood31,32. 
Here, we show that the maturation of the TC is associated with a 40% increase in tissue-
resident CD68+/CD163+ macrophages along with increase in IL10 and pro-fibrotic 
TGFβ mRNA levels within TCs. Besides, we did not observe a significant difference in 
CD68+/CD163+ macrophage population between CKD (46% of total macrophages) 
and WT animals (38%). Myofibroblast content was also similar between the groups. 
The latter most likely explains the similarity in collagen content in TCs as collagen is 
predominantly synthesized by (myo)fibroblasts.
Macrophages as precursors of myofibroblasts
During the development of the TC, we observed a gradual transition from granulation 
tissue towards circumferentially aligned SMA+ myofibroblasts, whereas a substantial 
proportion of the myofibroblasts in the TCs were derived from hematopoietic BMCs. 
The ability of BM-derived cells to differentiate into smooth muscle-like cells was first 
described by Campbell and coworkers in their experimental work on TC formation in 
the peritoneal cavity33. Subsequent studies from the same group confirmed the plasticity 
of peritoneal macrophages and their ability to transdifferentiate from a myeloid to 
mesenchymal phenotype34. In our model, 26% of myofibroblasts originated from BM-
derived macrophages, which illustrates the importance of macrophage-to-myofibroblast 
transition during the TC development. 
Contribution of bone marrow progenitor cells to TC formation
Possibly, other than BM-derived and/or tissue resident macrophages can contribute to 
TC formation. A recent study by Wang et al. showed that Sox10+ adult mouse stem cells 
found within the stroma of subcutaneous loose connective tissues, can contribute to 
encapsulation, fibrosis, and microvascularization of biomaterials upon implantation35. 
Interestingly, we observed a population of CD133+/GFP+ cells at the outer border of 
the TCs. Previous studies revealed that the membrane bound glycoprotein CD133 is 
expressed in mesenchymal stem cells (MSCs)36 and stromal cells37 within the BM. Both 
MSCs and stromal cells can give rise to human osteoblasts, adipocytes, chondrocytes 
as well as fibroblasts38,39. In this study, 24% CD133+/GFP+ cells were positive for 
SMA+ suggesting that CD133+ BM-derived cells can contribute to the myofibroblast 
population in mature tissue capsules.
CKD does not influence the cellular response during TC formation
As discussed above, the process of  TC formation involves an acute inflammatory 
response, followed by chronic inflammation and fibrosis culminating in the encapsulation 
of the implanted biomaterial. CKD is a pro-fibrotic condition associated with tissue 
scarring as well as kidney and cardiac fibrosis40-42. Excessive TGFβ signaling, which has 
been implicated in epithelial cells and fibroblasts in CKD41, can potentially enhance 
the process of TC formation in the subcutaneous space. On the other hand, CKD is 
associated with impaired function of both the innate and adaptive immune systems17. 
Circulating CD34+ progenitor cells are markedly reduced in patients with CKD. In 
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addition, monocyte-macrophages are more prone to apoptosis in CKD patients,43, 
which could also negatively infl uence TC formation in CKD patients.
In the present study, we did not observe a signifi cant eff ect of CKD on the cellular 
response upon implantation of the polymer rod. We hypothesize that the local foreign 
body response upon implantation of the polymer rod substantially diff ers from chronic 
infl ammation and subsequent tissue fi brosis as observed in various organs of patients 
with CKD.
After only 3 weeks, tissue capsules were well matured, indicating the importance of the 
acute response and that the local environment within subcutaneous space is suffi  cient to 
maintain the process of TC formation.  
Some aspects of our study require further discussion. One limitation in particular is 
the imperfect effi  cacy of the bone marrow transplantation, as only 75-80% of the cells 
in the peripheral blood were GFP+ after BM-transplantation. As a consequence, the 
contribution of bone marrow derived cells in TC formation might be underestimated. 
Our technology of tissue engineered blood vessels is aimed for patients with stage 5 of 
CKD which is defi ned as ESRD, when renal replacement therapy is required to survive. 
It needs to be  emphasized that the 5/6-nephrectomy model used in the current study 
does not fully resemble ESRD, as the glomerular fi ltration rate (GFR) is this model is 
around 29-15% of normal (CKD stage 4). Th us,  when extrapolating results to humans 
one should be cautious as TC formation in these rats might be slightly diff erent when 
compared to dialysis patients. Th e pathophysiological mechanisms underlying CKD are 
also diff erent between 5/6 nephrectomy animals and patients with CKD. Nevertheless, 
the 5/6-nephrectomy model in rats remains the most valuable and extensively investigated 
animal model mimicking human CKD44-47. 
Another limitation of this study is the inability to measure the mechanical strength of the 
TCs, an important parameter defi ning TC suitability for vascular grafting. However, a 
recent study performed in pigs demonstrates that the burst pressure and suture retention 
strength of the autologous TCs are suffi  cient to allow safe implantation in the arterial 
circulation13. 
Conclusion
Th is study illustrates that both BM-derived and resident cells contribute to the process of 
tissue response directed to a polymer rod that culminates in the formation of a collagen 
rich fi brocellular tissue capsule. BM-derived- as well as tissue resident macrophages serve 
as precursors of myofi broblasts in matured TCs. Notably, the presence of CKD does not 
signifi cantly alter the process of TC formation, which supports the suitability of our 
autologous vascular tissue engineering approach for future clinical use in CKD patients.
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Supplementary material
Supplementary Figure 1. Comparison of kidney histology between controls and rats under-
went 5/6 nephrectomy. 
(a.) Staining of kidney cortex with PAS (periodic acid-Schiff ) highlights basement membranes of glomeru-
lar capillary loops. Th e capillary loops of WT glomerulus are well-defi ned an thin, as compared to enlarged 
sclerotic glomeruli, regions of tubular necrosis and tubular cast formation (black arrows) in CKD rats 5 
weeks after 5/6 nephrectomy. (b.) Silver-stained kidney sections show pronounced glomerulosclerosis with 
dilated tubuli (black asterisks).
Supplementary Figure 2. Scanning electron microscopy images of (a) unmodifi ed Pa300, (b) Pa300 
chloroform-treated surface. Unmodifi ed rods have smooth surfaces while chloroform etching resulted in 
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Supplementary Figure 3. Progenitor CD133+ bone marrow derived cells in tissue capsule.
Immunofl uorescence staining of CD133+ stem/progenitor-cells (red color) originated from the GFP+ bone 
marrow (light blue color) detected in the TC at 3 weeks in WT and CKD groups. DAPI-nuclei blue.
Table 1  Primers used for in vitro experiments
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How it all started?
Th e view on renal replacement therapy was revolutionized in 1943 when the Dutch 
physician Dr. Willem Kollf built a fi rst prototype of a dialyzer1,2. Th e fi rst dialysis 
machines could get acute renal failure patients through a crisis until renal recovery, but 
the Achilles heel was a reliable access to the circulation for multiple dialysis sessions, 
which did not yet exist. Dialysis therapy for ESRD was fi rst successfully attempted by 
Scribner in 1960 (Seatle, USA) after Quinton built the fi rst shunt, based on a tefl on-
siliac loop externally placed between artery and vein of a patient3. Clyde Shields, a 
Boeing machinist, survived for 11 years after the insertion of Scribner’s fi rst AV shunt 
on 9 March 1960. Yet, Scribner-Quinton shunts usually lasted a few months or less, and 
were prone to clotting, skin necrosis, bleeding, and infection.
James E. Cimino and Michael J. Brescia (New York, USA) fi rst described a ‘simple 
venipuncture for hemodialysis’4 followed by the historical paper ‘Chronic hemodialysis 
using venipuncture and a surgically created arteriovenous fi stula’5 published in 1966 
in NEJM. Dr. Cimino says. “We were bold in using a procedure that had always been 
considered physiologically abnormal, but without adequate vascular access our patients 
were doomed.” Later, recalling the development of the AV fi stula, Dr. Cimino adds 
“I had no idea our technique would continue to be popular for so many years later. 
I thought the real advances were going to be in chemistry, and that scientists would 
develop a pill to help patients with end-stage renal disease”.
Where do we stand right now?
Even though at present kidney transplantation has become the preferred modality in 
kidney replacement therapy, the shortage of suitable donors is still persist. A considerable 
40% of ESRD patients still depend on dialysis6.  An adequately functioning AVF, 
described by Brescia and Cimino, remains the fi rst choice for chronic HD serving as 
a lifeline for a lifetime in hemodialysis patients. Up to now, international guidelines 
strongly encourage the creation of AVFs for HD vascular access over prosthetic AV 
grafts and CVCs7. Ironically, being preferred and most commonly used vascular access 
point, AVFs dysfunction remains a major source of morbidity for patients with ESRD. 
At current, only few eff ective therapies for this clinical problem are available. One of the 
reasons is limited understanding of the underlying mechanisms that lead to AVF failure. 
Th e availability of animal models made it possible to study the pathogenesis of vascular 
access failure and to evaluate new treatment candidates.
Although the exact pathophysiology of AVF failure is not completely understood, there 
is a general consensus between researchers that IH and inadequate OR are two main 
processes that contribute to AVF failure8,9. Recent studies have shown that the process 
of vascular adaptation is mainly driven by altered hemodynamics after AVF creation and 
is associated with an excessive infl ammatory response and proliferation and migration of 
arterial and venous VSMCs towards the intima at the site of anastomosis10-14.
Th e work described in this thesis aimed to further understand the pathobiology of 
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vascular access dysfunction and identify new therapeutic candidates to improve the 
current status of hemodialysis vascular access.
New insights into the pathobiology of AVF
Targeting inflammation in AVF maturation
Although several studies have shown that the adaptive response upon AVF creation 
triggers infiltration of macrophages and lymphocytes11 as well as upregulation of pro-
inflammatory cytokine production14, the role of inflammation in vascular remodeling 
upon AVF surgery has not been unraveled. Based on the previous knowledge that the 
TLR4 mediated inflammatory response contributes to several vascular pathologies15-17, 
in chapter 2 of this thesis we addressed the specific role of TLR4 homologue RP105 
in vascular remodeling, inflammation and VSMCs function in a murine model of AVF 
failure. We clearly show that RP105 deficiency affects the inflammatory and VSMC-
mediated response to injury during the course of AVF maturation, accumulating in an 
impaired outward remodeling of the venous outflow track of the AVF.
More detailed analysis of the effects of RP105 deficiency on the inflammatory response 
revealed strong accumulation of anti-inflammatory macrophages and an unexpected 
decrease in pro-inflammatory macrophages. The dominance of anti-inflammatory 
macrophages (> 90% of total macrophages) in the lesions at 2 weeks after AVF creation 
suggest either that in the current model pro-inflammatory response is completed 
at earlier time points, or that anti-inflammatory macrophages play a dominant role 
in the tissue response in murine AVF. Unfortunately, we did not study macrophage 
subpopulations at earlier time points. Concurrently, we observed a 50% decrease in 
MMP-activity in vivo, suggesting that the attenuation of vessel wall MMP activity limits 
venous OR in maturating AVFs.
VSMC content in AVFs from RP105 deficient mice was markedly decreased. In vitro, 
proliferation of venous VSMCs from RP105 deficient mice was reduced by 50%, whereas 
arterial VSMCs displayed a 50% decrease in migration. While VSMC proliferation in 
IH is generally considered to be detrimental, the process might be beneficial for OR, 
especially in the early phase of AVF maturation. In this respect, the observed reduction 
in venous outward remodeling, coupled with a reduction in proliferating venous VSMCs 
within AVFs, suggests that new drug targets designed to inhibit VSMCs proliferation 
could be detrimental for AVF maturation.
A striking observation in our studies was that RP105 diminution differentially affected 
arterial and venous VSMCs, as evidenced by RP105-specific effects on migration, 
proliferation and inflammatory cytokine production that differed substantially between 
these two cell sources. The endogenous expression levels of RP105 in arterial and venous 
VSMCs support this finding, along with differential expression profiles of associating 
TLR4-family members (including TLR4 and MD1). These findings illustrate the need 
for continued investigation of the phenotypic properties and functional characteristics 
of VSMCs in AVFs, in particular due to the contrasting lineage tracing studies detailing 
a predominance of arterial VSMCs18 versus venous VSMCs19 in venous IH following 
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AVF placement. Th is issue is further discussed in chapter 5 of this thesis.
Overall, results of this study demonstrate that deletion of TLR4 homologue RP105 
trigger alterations on various cell types involved in AVF maturation. In order to improve 
AVF outcomes, future therapeutic interventions targeting the TLR4/RP105 axis must 
include time-dependent and cell specifi c targeting approaches to steer the vascular 
remodeling response in the proper direction. 
Our next step in understanding the role of infl ammation in AVF maturation was 
aimed to understand whether inhibition of early infl ammatory response triggered by 
AVF surgery directly contributes to maturation failure. Glucocorticoids (GCs) are 
well known anti-infl ammatory drugs that bind to cytosolic glucocorticoid receptors in 
target cells, leading to the down-regulation in infl ammatory cytokine production and 
reduction in infl ammatory cell recruitment20,21. Despite being potent anti-infl ammatory 
drugs chronic and systemic use of GCs is limited due to high incidents of severe side-
eff ects22. In chapter 3 of this thesis we aimed to test whether administration of liposomal 
prednisolone (L-Pred) will result in local inhibition of infl ammatory response and, 
consequently, better AVF maturation. Targeted drug delivery achieved by incorporation 
of prednisolone into the liposomes hold great potential. As a result of enhanced vascular 
permeability caused by AVF surgery, circulating liposomal nanoparticles will extravasate 
and accumulate in the area around AV-anastomosis. To maximize effi  cacy and minimize 
toxicity of prednisolone is extremely important in such vulnerable patients as with 
ESRD.
First, using near infrared microscopy we demonstrated that liposomes extravasate 
in macrophages in the post-anastomotic area of the venous outfl ow tract—the 
most prone area of IH formation. As expected, we observed an 83% reduction in 
infi ltrating leukocytes from which subpopulation of T-lymphocytes and granulocytes 
were reduced by 86% and 51% respectively. Treatment of macrophages with L-Pred 
in vitro induced transition towards an anti-infl ammatory phenotype. Overall shift 
towards anti-infl ammatory state might have inhibited the recruitment of lymphocytes 
and granulocytes to the AV-anastomosis. Alternatively, release of prednisolone from 
macrophages might have had a direct eff ect on lymphocytes and granulocytes.
At a morphometrical level, treatment with L-Pred resulted in a 27% increase in outward 
remodeling and 47% increase in luminal area. Control mice treated with unencapsulated 
prednisolone or liposomes loaded with PBS did not show any eff ect on morphometry.
Th e exact mechanism by which liposomal prednisolone resulted in increased OR in 
murine AVF is not clear. We speculate that matrix metalloproteinases might contribute 
to this vascular response. Th e eff ect of MMPs on the vascular remodeling depend on 
the specifi c MMPs that are activated and the type of vascular injury23. Elegant study by 
Nieves Torres and coworkers24 suggests eff ect of MMP inhibition on venous outward 
remodeling in AVF. Indeed, adventitial delivery of a small hairpin RNA against the 
MMP ADAMTS-1, resulted in reduced macrophage infi ltration, decreased MMP9 
activity and enhanced outward remodeling in murine AVF.
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In our study, in vitro treatment of macrophages with L-Pred resulted in decreased 
MMP2 and MMP9 gene expression. Although we were not able to quantify MMP 
activity in vivo, we speculate that enhanced outward remodeling upon L-Pred treatment 
is mediated by the inhibition of inflammatory response and decrease MMP activity in 
macrophages.
In contrast to its effect on outward remodeling, no inhibitory effect of L-Pred on IH in 
the venous outflow tract was observed. These results deviate from other preclinical studies 
that evaluated the therapeutic effect of GCs in other vascular injury models, that have 
reported a strong inhibitory effect of dexamethasone on IH25-27. This discrepancy may 
result from a difference in potency between prednisolone and dexamethasone to inhibit 
VSMC proliferation28. Alternatively, it may relate to the difference in pathophysiological 
stimuli that contribute to IH after arterial injury, when compared to venous IH in 
AVF. While hemodynamic stimuli are considered to be of vital importance for IH29,30, 
the contribution of inflammation to IH in AVF might be limited, as suggested by our 
results. As a consequence, interventions that facilitate OR might therefore also result in a 
(modest) stimulation of IH. Ultimately, the net result of vascular remodeling in the AVF 
was increased luminal area of the venous outflow tract, that was mainly accountable by 
the OR process alone. Of note, a stimulatory effect of an intervention on OR is more 
important for the ultimate luminal surface area than the coinciding effect on IH, as 
there is a quadratic relationship between radius and surface area of the vessel.
In conclusion, liposomal prednisolone reduces the local inflammatory response and 
stimulates venous outward remodeling in murine AVF. Therefore, treatment with 
liposomal prednisolone might be valuable strategy to reduce AVF non-maturation. 
The efficacy of liposomal prednisolone to enhance radiocephalic AVF maturation in 
ESRD patients is currently being evaluated in the LIPMAT trial (clinicaltrial.gov ID 
NCT0249566), a double-blind, randomized, placebo-controlled trial31.
Targeting outward remodeling—a new direction for drug development?
While previous studies focused mainly on the development of strategies that aimed to 
reduce intimal hyperplasia, the current view on AVF maturation underscores the link 
between impaired outward remodeling and AVF failure8,32. Investigation of new targets 
that may promote outward remodeling might be of a great interest.
One of the appealing candidates is hormone relaxin (RLN2), originally known for its role 
in the growth and differentiation of the reproductive tract, and systemic hemodynamic 
adaptations during pregnancy, in particular vasodilatation33-35. In the context of AVF 
maturation, it is important to emphasize that RLN2 is expressed in the vessel wall36,37 
and that the observed vascular effects of RLN2 are mediated though an interaction 
with RXFP1 (relaxin/insulin-like peptide family receptor 1, original abbreviation 
LGR7), a G-protein-coupled receptor. In chapter 4 of this thesis we examined the 
consequences of disturbing this hormone-receptor balance in murine model of AVF 
failure. Our hypothesis was that RXFP1 deficiency disables local signal transduction 
from endogenous relaxin after AVF surgery resulting in reduced OR. Indeed, deficiency 
of RXFP1 resulted in a 22% decrease in vessel size at the venous outflow tract 14 days 
after AVF surgery.
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One of the main physiological actions of relaxin is its ability to remodel extracellular 
matrix components such as collagen and elastin in the cervix and myometrium during 
pregnancy38,39. In the settings of AVF, MMPs expression must be augmented to degrade 
and restructure the vascular matrix40 to promote outward remodeling. Interestingly, peri-
adventitial application of recombinant elastase has been shown to stimulate outward 
remodeling in a rabbit-model of AVF41. In our study we observed a 43% increase in 
elastin content in the lesions of RXFP1 defi cient mice which coincided with a 41% 
reduction in elastase activity, suggesting that RXFP1 is an important regulator of elastin 
degradation during AVF maturation. Furthermore, it supports the concept that venous 
outward remodeling requires relaxin axis-mediated augmentation of elastase activity.
Interestingly, relaxin-relaxin receptor interactions are known to mitigate vascular 
infl ammation, by inhibiting the upregulation of pro-infl ammatory cytokines42. In 
line with these observations, we found that RXFP1 defi ciency augments vascular 
infl ammation in AVFs, as illustrated by a 6-fold increase in CD45+ leukocytes, along 
with a 2-fold increase in MCP1 expression in the venous outfl ow tract.
Despite elevated levels of MCP1 in AVF lesions of RXFP1 defi cient mice, we 
unexpectedly did not observe eff ects on venous intimal hyperplasia. Further in vitro
experiments revealed that RXFP1 ablation caused a phenotypic switch of both arterial 
and venous VSMCs from a contractile towards a synthetic phenotype, as illustrated 
by augmentation of collagen, fi bronectin, TGFβ and PDGF mRNA expression levels. 
Functional studies revealed elevated migration of arterial and venous VSMCs isolated 
form RXFP1 defi cient mice. Th e question arises why RXFP1 defi ciency in vivo resulted 
in decreased outward remodeling and had no eff ect on intimal hyperplasia, whereas in 
vitro functional studies clearly show impact of RXFP1 defi ciency on VSMCs migration.
In this respect, it is important to notice that the effi  cacy of cell migration in vivo strongly
depends on the balance between cell deformability and ECM density, of which the latter 
is governed by the capacity of proteolytic enzymes to degrade matrix components43. 
Interestingly, RXFP1 defi ciency resulted in a signifi cant increase in elastin content as a 
result of decreased elastase activity. Th is preserved elastin density most likely explains 
why the increased migratory capacity of RXFP1 defi cient VSMCs in vitro, did not 
translate into enhanced intima hyperplasia in the venous outfl ow tract of AVF in RXFP1 
defi cient mice. Finally, RXFP1 and RLN expression levels were increased in human 
AVFs, as compared to unoperated cephalic veins, strongly suggesting that therapeutic 
targeting of this pathway in the context of AVF maturation could be benefi cial.
In conclusion, RXFP1 defi ciency hampers elastin degradation and results in induced 
vascular infl ammation after AVF surgery. Th ese processes impair outward remodeling in 
murine AVF, suggesting that the relaxin-axis could be a potential therapeutic target to 
promote AVF maturation.
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Remaining questions, points of consideration
One of the puzzling observations coming across this thesis is the difference in anatomical 
origin, gene expression profile and functional behavior of arterial and venous VSMCs. 
As the VSMCs and myofibroblasts are the main cell types contributing to intimal 
hyperplasia formation, it is of vital importance to gain more insights on the source of 
these cells within the neointima.
In chapter 5 of this thesis, the anatomical origin of VSMCs that are responsible for 
venous stenotic lesions in arteriovenous fistulas is discussed. In the past, migrated 
VSMCs from the venous tunica media were considered to be the most prominent 
source of neointimal cells, more recent studies suggest that venous adventitial fibroblasts, 
circulating vascular progenitor cells, and arterial VSMCs might contribute as well. 
Liang and coworkers in an elegant lineage tracing study suggested that VSMCs from the 
anastomosed artery contributed to as much as 50% of the VSMC compartment in the 
venous intima. The underlying mechanism was increased Notch signaling—a pathway 
critical in vascular development, in particular determining arterial versus venous vessel 
formation. 
Not only different origin of VSMCs, but their physiological state might steer the cellular 
response in AVF maturation, as recent study from Zhao et al. suggests. Genetic mapping 
displayed a dual function of mature VSMCs in AVF maturation, with differentiated/
contractile VSMCs contributing to medial wall thickening towards beneficial venous 
maturation and dedifferentiated/proliferative VSMCs contributing to detrimental 
neointimal hyperplasia44.
These findings underscore importance to further understand the role of different 
VSMCs in AVF maturation. While discussing implementation of the inhibitors of 
VSMCs proliferation, such as Notch/FSP-1, to improve AVF patency we should keep 
in mind that complete inhibition of VSMC proliferation and migration in the early 
phase after AVF surgery does not necessarily translate into a better functional outcome 
of AVFs. In previous chapters of this thesis we have already discussed importance of 
VSMC proliferation as a prerequisite for adequate outward remodeling of the involved 
blood vessels. Therefore, the timing of the application of novel interventions to inhibit 
VSMC proliferation could be crucial for its effect on the functional outcome of the AVF.
Another attractive aim for the future studies is to optimize venous adaptation to the 
arterial environment during postsurgical processes.
Beyond arteriovenous fistula
Even though AVF is preferred modality of hemodialysis vascular access site, native 
veins are often unavailable due to preexisting vascular pathology12. Utilization of 
synthetic vascular grafts predominantly results from the development of intimal 
hyperplasia ultimately leading to graft occlusion, and a relatively high risk of infectious 
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complications45,46. To create tissue engineered vascular grafts is one of the promising 
solutions to overcome current limitations of synthetic grafts and diseased native blood 
vessels. Previously, we developed a method to generate autologous TEBVs in vivo, which 
is based on the FBR directed to a subcutaneously implanted polymer rod that culminates 
in the formation of a fi brocellular TC47. Th us far, the origin of the cells present within 
the TCs remains unknown. Understanding the origin of cells present in the TC is of 
vital importance for its application as vascular grafts, as various disease conditions such 
as diabetes mellitus and CKD coincide with impaired function of BM-derived cells48,49, 
which could hamper TC formation.
In chapter 6 of this thesis, we elucidated the contribution of BM-derived cells in TC 
formation.  For this purpose, we implanted polymer rods in the subcutis of rats after 
receiving BM-transplants with GFP-labeled BM cells. In addition, a CKD model was 
incorporated, as we aim to utilize the engineered vascular grafts for patients with ESRD 
requiring vascular access for hemodialysis.
In the early phase after rod implantation, TCs were mainly composed of CD68+
macrophages which where predominantly located along the inner border, adjacent to 
the polymeric rod. On average, 13% of CD68+ macrophages were GFP+ cells, indicating 
BM origin. Several studies suggest that cells within the local tissue environment, such as 
tissue-resident macrophages, also contribute to the foreign body response and play major 
role in the formation of engineered tissue50,51. Here, we show that the maturation of the 
TC is associated with a 40% increase in repair associated CD68+/CD163+ macrophages 
along with increase in IL10 and pro-fi brotic TGFβ mRNA levels within TCs.
During the development of the TC, we observed a gradual transition from granulation 
tissue towards circumferentially aligned SMA+ myofi broblasts. Macrophage-to-
myofi broblasts diff erentiation appeared to play an important role in TC formation as 26% 
of SMA+/GFP+ myofi broblasts co-expressed macrophage marker CD68. Interestingly, 
we detected a population of CD133+ bone marrow progenitor cells, positive for GFP, 
from which 24% were positive for SMA+ suggesting that CD133+ BM-derived cells can 
also contribute to the myofi broblast population in mature TC.
Finally, we did not observe a signifi cant eff ect of CKD on the cellular response upon 
implantation of the polymer rod. We hypothesize that the local foreign body response 
upon implantation of the polymer rod is substantially diff ers from chronic infl ammation 
and subsequent tissue fi brosis as observed in various organs of patients with CKD. After 
only 3 weeks, tissue capsules were well matured, indicating the importance of the acute 
response and that the local environment within subcutaneous space is suffi  cient to 
maintain the process of TC formation.
Overall results from our study show that both BM-derived, as well as tissue resident cells, 
contribute to TC formation, whereas macrophages serve as precursors of myofi broblasts 
in mature TCs. Th e presence of CKD did not signifi cantly alter the process of TC 
formation, which supports our approach for future clinical use in ESRD patients.
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Final conclusion
Dysfunction of vascular access remains a major clinical problem responsible for high 
morbidity and substantial health care costs in patients required chronic hemodialysis 
treatment. Despite the magnitude of this clinical problem, there have been no major 
novel therapeutic interventions in the field of hemodialysis access for the past few 
decades.
Even though nowadays more and more attention is drawn onto importance to understand 
pathobiology of vascular access dysfunction the complete picture is still missing.
In our group, we developed a unique murine AVF model, which has a configuration 
similar to the one used most frequently in humans (venous end-to-arterial side). This 
work has revealed that stenotic lesions in this murine AVF model closely resemble that 
in human failed fistulas. Specifically, pathological lesions are localized near the venous 
anastomosis and are characterized by proliferating VSMCs, infiltration of leukocytes 
and accumulation of extracellular matrix components.
Work described in this thesis, further shed light onto our understanding of the 
pathophysiology of AVF failure and identified new therapeutic targets aimed to improve 
patency of AV-fistula.
We first explored the role of inflammation in vascular remodeling upon AVF surgery. We 
unraveled the complex role of natural agonist of TLR4 ̶ RP105 in the pathophysiology 
of AVF failure identifying a novel relationship between inflammation and VSMC 
function.
Knowing that AVF surgery triggers influx of inflammatory cells in the vessel wall, in our 
subsequent study we focused on the strategy to reduce inflammation by administering 
liposomal prednisolone. We observed reduction in the local inflammatory response and 
increase in the venous outward remodeling, suggesting that local delivery of prednisolone 
via liposomes is beneficial for AVF maturation.
Based on the evolving concept of the importance of the outward remodeling in AVF 
maturation next, we evaluated the role of relaxin pathway as potential contributor to OR 
in AVF maturation. Deficiency of the relaxin receptor resulted in an impaired outward 
remodeling in the murine AVF, suggesting that the relaxin-axis could be a potential 
therapeutic target to promote AVF maturation. Together with our collaborators at the 
university Miami, Florida in near future we aim to test therapeutic agonist of relaxin in 
our AVF model and in hemodialysis patients.
In parallel with testing new therapeutics to improve maturation and patency of 
native AVFs, our group is working on developing TEBVs which could offer a suitable 
alternative for arteriovenous conduits. In collaboration with University of California, 
Los Angeles, we performed a lineage tracing to study the contribution of bone marrow 
derived cells to TEBV formation and the impact of CKD onto the process of TEBV 
formation. Importantly, the CKD condition did not significantly alter the process of 
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TEBV formation, supporting our technology to be relevant for future clinical use in 
ESRD patients.
Some aspects of our studies require further discussion. One of the limitations in our 
experimental setup is the inability to perform fl ow measurements and cannulations of 
the murine AVF, as an adequate blood fl ow volume and the cannulability of the AVF are 
the main characteristics of functional hemodialysis access.
Another point to consider is that our studies were performed in healthy mice. Recently 
established CKD model described by Kang et al. demonstrated that fi stula maturation is 
aff ected by CKD, specifi cally the chronic accumulation of waste products and uremic 
toxins in the blood impacted AVF fl ow, resulting in increased venous wall thickness 
and thrombus formation52.
However, we believe that decision on combining AVF model with CKD, should be 
well-reasoned and based not only on blind faith, but ethical justifi cation. Welfare 
of laboratory animals is an important parameter of consideration while designing a 
new study. In studies aimed to identify new pathways involved in the pathobiology 
of AVF, the relevance of CKD implementation should be questioned.
For many years, vascular access was regarded as an exclusively surgical problem. Up to 
now, advances in vascular access treatments are limited. Medical professionals often 
focusing on the one-center experience and neglect importance to study the fundamental 
mechanisms leading to an arteriovenous fi stula failure. It is time to recognize vascular 
access as truly multi-disciplinary science and to bring fi elds of molecular biology, 
medicine and new advances of biomaterials for local drug delivery to improve current 
patient care.
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Niertransplantatie is momenteel de beste behandeling voor chronisch nierfalen, er is 
echter een groot tekort aan donoren en sommige patiënten zijn niet in de conditie om 
veilig een niertransplantatie te ondergaan. Derhalve zijn 40% van de patiënten met 
eindstadium nierfalen nog steeds afhankelijk van dialyse. De meest voorkomende vorm 
van dialyse is hemodialyse. Tijdens de hemodialyse behandeling wordt het extracorporaal 
verwijderen van afvalstoff en en het verwijdering van vloeistoff en direct via het bloed 
uitgevoerd. Om de hemodialyse procedure te beginnen, is er een toegang tot een bloedvat 
met een hoge bloedstroomsnelheid nodig. Tot op het heden is de arterioveneuze fi stel 
(AVF), een directe verbinding tussen een arterie en een vene, de gouden standaard van 
hemodialyse vaattoegang.
Complicaties van de vaattoegang zijn een belangrijke oorzaak van morbiditeit voor 
patiënten met eindstadium nierfalen. Om de vaattoegang te kunnen verbeteren is het 
van groot belang om de onderliggende mechanismen achter AVF dysfunctie beter te 
begrijpen. Alleen dan kunnen nieuwe eff ectieve therapieën worden ontwikkeld.
Het onderzoek in dit proefschrift is gericht op het beter begrijpen van de pathofysiologie 
van vaattoegang disfunctie, en nieuwe therapeutische targets te identifi ceren om de 
vaattoegang voor dialyse te verbeteren.
Nieuwe inzichten in de pathobiologie van AVF
Infl ammatie in AVF maturatie
Eerder onderzoek heeft aangetoond dat het proces van vaatadaptatie na het maken van 
de AVF gepaard gaat met een excessieve infl ammatoire response.
In hoofdstuk 2 en 3 van dit proefschrift zal de bijdrage van infl ammatie op AVF 
maturatiefalen worden bestudeerd.
Gebaseerd op bestaande kennis dat de toll-like receptor 4 (TLR4) gemedieerde 
infl ammatoire response bijdraagt aan verschillende vaatziekten, wordt in hoofdstuk 2
van dit proefschrift de specifi eke rol van TLR4 homoloog RP105 met betrekking tot 
vaatremodelering, infl ammatie, en  gladde spiercelfunctie in een muis model van AVF 
falen beschreven.
Een meer gedetailleerde analyse van het eff ect van RP105 defi ciëntie op de infl ammatoire 
response toonde een sterke accumulatie van anti-infl ammatoire macrofagen en een 
vermindering in de hoeveelheid pro-infl ammatoire macrofagen. Daarnaast resulteerde 
de afwezigheid van RP105 in een duidelijke vermindering van de hoeveelheid gladde 
spiercellen in de AVF in muizen. Een onverwachte bevinding in deze studie was dat 
RP105 vermindering de veneuze en arteriële gladde spiercellen anders beïnvloed. 
Samenvattend heeft de deletie van RP105 impact op de verschillende celtypes die 
betrokken zijn bij AVF maturatie. Om de uitkomsten van AVFs te verbeteren is het van 
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belang om toekomstige TLR4/RP105 gerichte therapieën cel specifiek te maken om de 
vasculaire response in de juiste richting te leiden.
De volgende stap in het begrijpen van de rol van inflammatie in AVF maturatie was om 
te testen of het remmen van de vroege inflammatoire response in de vaatwand resulteert 
in een betere uitkomst van AVFs. In hoofdstuk 3 van dit proefschrift wordt liposomaal 
prednisolon, een bekende anti-inflammatoire stof, toegediend in muizen met een AVF. 
Door de incorporatie van prednisolon in de liposomen wordt een optimale locatie-
specifieke concentratie van het geneesmiddel bereikt waardoor minder systemische 
bijwerkingen optreden van prednisolon. Dit onderzoek liet zien dat behandeling met 
liposomaal prednisolon resulteert in een 83% verminderingen van ontstekingscellen in 
de vaatwand en een bijna 50% toename in het lumenoppervlak van de AVF. Daarom 
zou liposomaal prednisolon een strategie kunnen zijn om de bruikbaarheid van AVFs als 
vaattoegang voor dialyse te verbeteren. Het effect van liposomaal prednisolon om AVFs 
te verbeteren in patiënten met nierfalen wordt momenteel geëvalueerd in de LIPMAT 
studie (clinicaltrial.gov ID NCT0249566), een dubbel geblindeerde, gerandomiseerde, 
placebo gecontroleerde klinische studie.
Stimulatie van outward remodeling -  een nieuwe optie om AVFs te verbeteren? 
De meeste studies die zijn verricht om AVF functie te verbeteren richten zich op de 
ontwikkeling van strategieën ter vermindering van intimal hyperplasie. Er zijn echter 
steeds meer aanwijzingen dat het bevorderen van de groei van de betrokken bloedvaten 
(outward remodeling) een goede optie zou kunnen helpen om AVF falen te voorkomen.
 
Het hormoon relaxin (RLN2) speelt mogelijk een rol in de groei van bloedvaten. Relaxin 
draagt immers in belangrijke mate bij aan de aanpassing van bloedvaten tijdens de 
zwangerschap (met name vasodilatatie). Zowel RLN2 als de relaxin-receptor (RXFP1) 
komen tot expressie in de wand van bloedvaten. In hoofdstuk 4 van dit proefschrift 
wordt onderzocht wat het effect is van het wegnemen van relaxin op AVFs in muizen 
die geen relaxin-receptor hebben. Onze hypothese is dat het ontbreken van RXFP1 
resulteert in een verminderde outward remodeling. In dit onderzoek leidde een tekort 
aan RXFP1 inderdaad tot een 22% vermindering in vaatoppervalk ter plaatse van 
veneuze component van de AVF.
Een van de voornaamste fysiologische werkingen van relaxin is het remodelleren 
van extracellulaire matrix componenten zoals collageen en elastine in de cervix en 
myometrium tijdens de zwangerschap. In ons onderzoek observeerden wij een 43% 
vermindering in de hoeveelheid elastine in de lesies van RXFP1 deficiënte muizen. Dit 
kwam overeen met een 41% reductie in elastase activiteit, wat aangeeft dat RXFP1 en 
belangrijke regulator is van elastine degradatie tijdens AVF maturatie.
De interacties van relaxin met de  relaxin receptor bevordert inflammatie. In ons 
onderzoek ontdekten we dat RXFP1 deficiëntie ook de vaatinflammatie in AVF 
beïnvloedt, geïllustreerd door een 6-voudige toename van leukocyten in de vaatwand, 
en een 2-voudige verhoging van MCP-1 expressie, een belangrijk pro-inflammatoir 
cytokine. Ook in humane AVFs konden we aantonen dat de expressie niveaus van 
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RXFP1 en RLN verhoogd zijn ten opzicht van normale bloedvaten. Deze bevinding 
ondersteunt de potentie van relaxin als  therapeutisch target bij het stimuleren van AVF 
maturatie.
Vervolgonderzoek
Een van de meest opmerkelijke bevindingen in dit proefschrift is het verschil tussen de 
anatomische origine, genexpressie profi el en functioneel gedrag van arteriële en veneuze 
gladde spiercellen.
In hoofdstuk 5 van deze thesis wordt de anatomische origine van VSMCs in stenotische 
lesies besproken. Tot het heden werden gladde spiercellen die migreerde van de 
middenlaag van bloedvaten (tunica media) gezien als de meest prominente oorsprong 
van neointimal cellen. Recent onderzoek wijst echter uit dat veneuze adventitiele 
fi broblasten, circulerende progenitor cellen, en arteriële gladde spiercellen ook bijdragen 
aan stenose in AVFs. 
Beyond arteriovenous fi stulas
Hoewel een AVF de meest gebruikte vorm van vaattoegang is, zijn geschikte venen 
niet altijd beschikbaar. Het gebruik van kunststof bloedvaten wordt beperkt door 
slechte uitkomsten, waarbij de kunststof vaten veelal dichtgroeien en verstopt raken en 
een hoog risico van infectie met zich mee brengen. Tissue-engineered bloedvaten zijn 
een veelbelovende oplossing om de nadelen van synthetische, en pathologische vaten 
omzeilen. 
De afgelopen jaren hebben wij een methode ontwikkeld waarbij nieuwe bloedvaten 
worden gemaakt door de patiënt zelf, door een polymeer staafj e onderhuids te 
implanteren. De zogenaamde vreemd lichaamsreactie leidt tot de formatie van een 
fi brocellulaire weefselcapsule, die gebruikt kan worden als lichaamseigen bloedvat. 
Tot op het heden blijft de origine van de cellen in deze weefselcapsule onbekend. In 
hoofdstuk 6 van dit proefschrift wordt de contributie van beenmerg cellen in weefsel 
capsule vorming onderzocht. Polymere staafj es werden onderhuids geïmplanteerd in 
ratten die een beenmerg transplantatie van  speciaal-gelabelde cellen (met GFP) hebben 
gekregen. Een nierfalenmodel werd ook geïncorporeerd, aangezien het doel is om 
deze weefsel capsules te implementeren als vaat toegang in patiënten met eindstadium 
nierfalen.
In de vroege fase na het implanteren van de staafj es bestaan de weefselcapsules grotendeels 
uit macrofagen. Gemiddeld bleek 13% van de macrofagen in  de weefselcapsules 
afkomstig uit het beenmerg. Tijdens de ontwikkeling van de weefselcapsule veranderd 
het weefsel van ontstekingsweefsel met macrofagen in granulatieweefsel, vooral 
bestaand uit myofi broblasten. De macrofaag naar myofi broblast diff erentiatie leek een 
belangrijke rol te spelen in de vorming van de weefsel capsule aangezien 26% van de 
GFP- myofi broblasten een macrofaag marker tot expressie brachten.
Deze resultaten geven aan dat cellen vanuit het beenmerg en lokale cellen uit de 
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onderhuid bijdragen aan de weefselcapsule vorming. De aanwezigheid van nierfalen 
had geen invloed op de vorming van de weefselcapsules, wat aangeeft ons doel versterkt 
van het toepassen van deze techniek in patiënten met eind stadium niet falen.
Tot slot geeft hoofdstuk 7 een beschouwing en discussie van alle studies die in dit 
proefschrift zijn beschreven.
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